(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 November 2000 (30.11.2000)

PCT

(10) International Publication Number
WO 00/72021 A2

(51) International Patent Classification[7]: G01N 33/574, C12Q 1/68, A61K 39/00, 48/00, 39/395, C12N 15/63, 5/10, C07K 14/47, 7/04, A61K 35/14, C07K 16/18

(21) International Application Number: PCT/US00/14391

(22) International Filing Date: 24 May 2000 (24.05.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/320,092 26 May 1999 (26.05.1999) US

(71) Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/US]; 605 Third Avenue, New York, NY 10158 (US).

(72) Inventors: KUIMOV, Alexander; Belozersky Institute of Physio-Chemical Biology, Moscow State University, Moscow (RU). LAGARKOVA, Marka; Belozersky Institute of Physio-Chemical Biology, Moscow State University, Moscow (RU). KOROLEVA, Ekaterina; Belozersky Institute of Physio-Chemical Biology, Moscow State University, Moscow (RU). TURETSKAYA, Regina; Engelhardt Institute of Moloculer Biology, Russian Academy of Sciences, Moscow (RU). VDOVICHENKO, Konstantin; Belozersky Institute of Physio-Chemical Biology, Moscow State University, Moscow (RU). MESCHERYAKOV, Andrei; Oncological Research Center, Russian Academy of Medical Science, Moscow (RU). LITCHINITSER, Mikhail; Oncological Research Center, Russian Academy of Medical Science, Moscow (RU). KUPRASH, Dmitry; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow (RU). NEDOSPASOV, Sergei; Belozersky Institute of Physio-Chemical Biology, Moscow State University, Moscow (RU). TURECI, Ozlem; Innere Medizin 1, D-66421 Homburg/Saar (DE). SAHIN, Ugur; Innere Medizin 1, D-66421 Homburg/Saar (DE). PFRUENDSCHUH, Michael; Innere Medizin 1, D-66421 Homburg/Saar (DE). OLD, Lloyd, J.; Ludwig Institute for Cancer Research, 605 Third Avenue, New York, NY 10158 (US). KNUTH, Alex; Hohl 2-28, D-60488 Frankfurt am Main (DE). JAGER, Elke; Hohl 2-28, D-60488 Frankfurt am Main (DE).

(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States *(national)*: AU, CA, CN, JP, KR.

(84) Designated States *(regional)*: European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published:
— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 00/72021 A2

(54) Title: CANCER ASSOCIATED ANTIGENS AND USES THEREFOR

(57) Abstract: Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in breast cancer and/or T cell leukemia cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed inpatients afflicted with cancer. The invention provides, *inter alia*, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

CANCER ASSOCIATED ANTIGENS AND USES THEREFOR

Field of the Invention

The invention relates to nucleic acids and encoded polypeptides which are cancer
5 associated antigens expressed in patients afflicted with breast cancer and/or T cell leukemia. The invention also relates to agents which bind the nucleic acids or polypeptides. The nucleic acid molecules, polypeptides coded for by such molecules and peptides derived therefrom, as well as related antibodies and cytolytic T lymphocytes, are useful, *inter alia*, in diagnostic and therapeutic contexts.

10

Background of the Invention

The mechanism by which T cells recognize foreign materials has been implicated in cancer. A number of cytolytic T lymphocyte (CTL) clones directed against autologous melanoma antigens, testicular antigens, and melanocyte differentiation antigens have been
15 described. In many instances, the antigens recognized by these clones have been characterized.

The use of autologous CTLs for identifying tumor antigens requires that the target cells which express the antigens can be cultured *in vitro* and that stable lines of autologous CTL clones which recognize the antigen-expressing cells can be isolated and propagated.
20 While this approach has worked well for melanoma antigens, other tumor types, such as epithelial cancers including breast and colon cancer, have proved refractory to the approach.

More recently another approach to the problem has been described by Sahin et al. (*Proc. Natl. Acad. Sci. USA* 92:11810-11813, 1995). According to this approach, autologous antisera are used to identify immunogenic protein antigens expressed in cancer cells by
25 screening expression libraries constructed from tumor cell cDNA. Antigen-encoding clones so identified have been found to have elicited an high-titer humoral immune response in the patients from which the antisera were obtained. Such a high-titer IgG response implies helper T cell recognition of the detected antigen. These tumor antigens can then be screened for the presence of MHC/HLA class I and class II motifs and reactivity with CTLs.

30 Since the individual tumor antigens presently known may be expressed only in a fraction of tumors, the availability of additional tumor antigens would significantly enlarge the proportion of patients who are potentially eligible for therapeutic interventions. Thus there presently is a need for additional tumor antigens for development of therapeutics and

diagnostics applicable to a greater number of cancer patients having various cancers.

The invention is elaborated upon further in the disclosure which follows.

Summary of the Invention

5 Autologous antibody screening has now been applied to breast cancer and T cell leukemia using antisera from cancer patients. Numerous cancer associated antigens have been identified. The invention provides, *inter alia*, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and 10 peptides and CTLs which recognize the proteins and peptides. Fragments including functional fragments and variants of the foregoing also are provided. Kits containing the foregoing molecules additionally are provided. The foregoing can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.

15 Prior to the present invention, only a handful of cancer associated genes had been identified in the past 20 years. The invention involves the surprising discovery of several genes, some previously known and some previously unknown, which are expressed in individuals who have cancer. These individuals all have serum antibodies against the proteins (or fragments thereof) encoded by these genes. Thus, abnormally expressed genes are 20 recognized by the host's immune system and therefore can form a basis for diagnosis, monitoring and therapy.

The invention involves the use of a single material, a plurality of different materials and even large panels and combinations of materials. For example, a single gene, a single protein encoded by a gene, a single functional fragment thereof, a single antibody thereto, etc. 25 can be used in methods and products of the invention. Likewise, pairs, groups and even panels of these materials and optionally other cancer associated antigen genes and/or gene products can be used for diagnosis, monitoring and therapy. The pairs, groups or panels can involve 2, 3, 4, 5 or more genes, gene products, fragments thereof or agents that recognize such materials. A plurality of such materials are not only useful in monitoring, typing, 30 characterizing and diagnosing cells abnormally expressing such genes, but a plurality of such materials can be used therapeutically. An example of the use of a plurality of such materials for the prevention, delay of onset, amelioration, etc. of cancer cells, which express or will express such genes prophylactically or acutely. Any and all combinations of the genes, gene

products, and materials which recognize the genes and gene products can be tested and identified for use according to the invention. It would be far too lengthy to recite all such combinations; those skilled in the art, particularly in view of the teaching contained herein, will readily be able to determine which combinations are most appropriate for which
5 circumstances.

As will be clear from the following discussion, the invention has *in vivo* and *in vitro* uses, including for therapeutic, diagnostic, monitoring and research purposes. One aspect of the invention is the ability to fingerprint a cell expressing a number of the genes identified according to the invention by, for example, quantifying the expression of such gene products.
10 Such fingerprints will be characteristic, for example, of the stage of the cancer, the type of the cancer, or even the effect in animal models of a therapy on a cancer. Cells also can be screened to determine whether such cells abnormally express the genes identified according to the invention.

The invention, in one aspect, is a method of diagnosing a disorder characterized by
15 expression of a cancer associated antigen precursor coded for by a nucleic acid molecule. The method involves the steps of contacting a biological sample isolated from a subject with an agent that specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an MHC, preferably an HLA, molecule, wherein the nucleic acid molecule is a NA Group 1 nucleic acid molecule, and
20 determining the interaction between the agent and the nucleic acid molecule, the expression product or fragment of the expression product as a determination of the disorder.

In one embodiment the agent is selected from the group consisting of (a) a nucleic acid molecule comprising NA Group 1 nucleic acid molecules or a fragment thereof, (b) a nucleic acid molecule comprising NA Group 3 nucleic acid molecules or a fragment thereof,
25 (c) a nucleic acid molecule comprising NA Group 5 nucleic acid molecules or a fragment thereof, (d) an antibody that binds to an expression product, or a fragment thereof, of NA group 1 nucleic acids, (e) an antibody that binds to an expression product, or a fragment thereof, of NA group 3 nucleic acids, (f) an antibody that binds to an expression product, or a fragment thereof, of NA group 5 nucleic acids, (g) and agent that binds to a complex of an
30 MHC, preferably HLA, molecule and a fragment of an expression product of a NA Group 1 nucleic acid, (h) an agent that binds to a complex of an MHC, preferably HLA, molecule and a fragment of an expression product of a NA group 3 nucleic acid, and (i) an agent that binds to a complex of an MHC, preferably HLA, molecule and a fragment of an expression product

of a NA Group 5 nucleic acid.

The disorder may be characterized by expression of a plurality of cancer associated antigen precursors. Thus the methods of diagnosis may include use of a plurality of agents, each of which is specific for a different human cancer associated antigen precursor (including at least one of the cancer associated antigen precursors disclosed herein), and wherein said plurality of agents is at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 such agents.

In each of the above embodiments the agent may be specific for a human cancer associated antigen precursor, including the breast cancer and T cell leukemia associated antigen precursors disclosed herein.

In another aspect the invention is a method for determining regression, progression or onset of a condition characterized by expression of abnormal levels of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule. The method involves the steps of monitoring a sample, from a subject who has or is suspected of having the condition, for a parameter selected from the group consisting of (i) the protein, (ii) a peptide derived from the protein, (iii) an antibody which selectively binds the protein or peptide, and (iv) cytolytic T cells specific for a complex of the peptide derived from the protein and an MHC molecule, as a determination of regression, progression or onset of said condition. In one embodiment the sample is a body fluid, a body effusion or a tissue.

In another embodiment the step of monitoring comprises contacting the sample with a detectable agent selected from the group consisting of (a) an antibody which selectively binds the protein of (i), or the peptide of (ii), (b) a protein or peptide which binds the antibody of (iii), and (c) a cell which presents the complex of the peptide and MHC molecule of (iv). In a preferred embodiment the antibody, the protein, the peptide or the cell is labeled with a radioactive label or an enzyme. The sample in a preferred embodiment is assayed for the peptide.

According to another embodiment the nucleic acid molecule is one of the following: a NA Group 3 molecule or a NA Group 5 molecule. In yet another embodiment the protein is a plurality of proteins, the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins.

The invention in another aspect is a pharmaceutical preparation for a human subject. The pharmaceutical preparation includes an agent which when administered to the subject enriches selectively the presence of complexes of an HLA molecule and a human cancer

associated antigen, and a pharmaceutically acceptable carrier, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule which comprises a NA Group 1 molecule. In one embodiment the nucleic acid molecule is a NA Group 3 nucleic acid molecule.

5 The agent in one embodiment comprises a plurality of agents, each of which enriches selectively in the subject complexes of an HLA molecule and a different human cancer associated antigen. Preferably the plurality is at least two, at least three, at least four or at least 5 different such agents.

In another embodiment the agent is selected from the group consisting of (1) an 10 isolated polypeptide comprising the human cancer associated antigen, or a functional variant thereof, (2) an isolated nucleic acid operably linked to a promoter for expressing the isolated polypeptide, or functional variant thereof, (3) a host cell expressing the isolated polypeptide, or functional variant thereof, and (4) isolated complexes of the polypeptide, or functional variants thereof, and an HLA molecule.

15 The agent may be a cell expressing an isolated polypeptide. In one embodiment the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof. In another embodiment the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof, and wherein the cell expresses an HLA molecule that binds the polypeptide. 20 The cell can express one or both of the polypeptide and HLA molecule recombinantly. In preferred embodiments the cell is nonproliferative. In yet another embodiment the agent is at least two, at least three, at least four or at least five different polypeptides, each representing a different human cancer associated antigen or functional variant thereof.

The agent in one embodiment is a PP Group 2 polypeptide. In other embodiments the 25 agent is a PP Group 3 polypeptide or a PP Group 4 polypeptide.

In an embodiment each of the pharmaceutical preparations described herein also includes an adjuvant.

According to another aspect the invention, a composition is provided which includes an isolated agent that binds selectively a PP Group 1 polypeptide. In separate embodiments 30 the agent binds selectively to a polypeptide selected from the following: a PP Group 2 polypeptide, a PP Group 3 polypeptide, a PP Group 4 polypeptide, and a PP Group 5 polypeptide. In other embodiments, the agent is a plurality of different agents that bind selectively at least two, at least three, at least four, or at least five different such polypeptides.

In each of the above described embodiments the agent may be an antibody.

In another aspect the invention is a composition of matter composed of a conjugate of the agent of the above-described compositions of the invention and a therapeutic or diagnostic agent. Preferably the conjugate is of the agent and a therapeutic or diagnostic that is an 5 antineoplastic.

The invention in another aspect is a pharmaceutical composition which includes an isolated nucleic acid molecule selected from the group consisting of: (1) NA Group 1 molecules, and (2) NA Group 2 molecules, and a pharmaceutically acceptable carrier. In one embodiment the isolated nucleic acid molecule comprises a NA Group 3 or NA Group 4 10 molecule. In another embodiment the isolated nucleic acid molecule comprises at least two isolated nucleic acid molecules coding for two different polypeptides, each polypeptide comprising a different cancer associated antigen.

Preferably the pharmaceutical composition also includes an expression vector with a promoter operably linked to the isolated nucleic acid molecule. In another embodiment the 15 pharmaceutical composition also includes a host cell recombinantly expressing the isolated nucleic acid molecule.

According to another aspect of the invention a pharmaceutical composition is provided. The pharmaceutical composition includes an isolated polypeptide comprising a PP Group 1 or a PP Group 2 polypeptide, and a pharmaceutically acceptable carrier. In one 20 embodiment the isolated polypeptide comprises a PP Group 3 or a PP Group 4 polypeptide.

In another embodiment the isolated polypeptide comprises at least two different polypeptides, each comprising a different cancer associated antigen at least one of which is encoded by a NA group 1 molecule as disclosed herein. In separate embodiments the isolated polypeptides are selected from the following: PP Group 3 polypeptides or HLA binding 25 fragments thereof and PP Group 5 polypeptides or HLA binding fragments thereof.

In an embodiment each of the pharmaceutical compositions described herein also includes an adjuvant.

Another aspect the invention is an isolated nucleic acid molecule comprising a NA Group 3 molecule. Another aspect the invention is an isolated nucleic acid molecule 30 comprising a NA Group 4 molecule.

The invention in another aspect is an isolated nucleic acid molecule selected from the group consisting of (a) a fragment of a nucleic acid selected from the group of nucleic acid molecules consisting of SEQ ID Nos:1, 3, 4, 6, 7, 9 and 16, of sufficient length to represent a

sequence unique within the human genome, and identifying a nucleic acid encoding a human cancer associated antigen precursor, (b) complements of (a), provided that the fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from the sequence group consisting of (1) sequences having the GenBank accession numbers of Table 4, (2) complements of (1), and (3) fragments of (1) and (2).

In one embodiment the sequence of contiguous nucleotides is selected from the group consisting of: (1) at least two contiguous nucleotides nonidentical to the sequences in Table 4, (2) at least three contiguous nucleotides nonidentical to the sequences in Table 4, (3) at least four contiguous nucleotides nonidentical to the sequences in Table 4, (4) at least five contiguous nucleotides nonidentical to the sequences in Table 4, (5) at least six contiguous nucleotides nonidentical to the sequences in Table 4, or (6) at least seven contiguous nucleotides nonidentical to the sequences in Table 4.

In another embodiment the fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, 200 nucleotides, 1000 nucleotides and every integer length therebetween.

In yet another embodiment the molecule encodes a polypeptide which, or a fragment of which, binds a human HLA receptor or a human antibody.

Another aspect of the invention is an expression vector comprising an isolated nucleic acid molecule of the invention described above operably linked to a promoter.

According to one aspect the invention is an expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 1 or Group 2 molecule. In another aspect the invention is an expression vector comprising a NA Group 1 or Group 2 molecule and a nucleic acid encoding an MHC, preferably HLA, molecule.

In yet another aspect the invention is a host cell transformed or transfected with an expression vector of the invention described above.

In another aspect the invention is a host cell transformed or transfected with an expression vector comprising an isolated nucleic acid molecule of the invention described above operably linked to a promoter, or an expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 1 or 2 molecule and further comprising a nucleic acid encoding HLA.

According to another aspect of the invention an isolated polypeptide encoded by the

isolated nucleic acid molecules the invention, described above, is provided. These include PP Group 1-5 polypeptides. The invention also includes a fragment of the polypeptide which is immunogenic. In one embodiment the fragment, or a portion of the fragment, binds HLA or a human antibody.

5 The invention includes in another aspect an isolated fragment of a human cancer associated antigen precursor which, or portion of which, binds HLA or a human antibody, wherein the precursor is encoded by a nucleic acid molecule that is a NA Group 1 molecule. In one embodiment the fragment is part of a complex with HLA. In another embodiment the fragment is between 8 and 12 amino acids in length. In another embodiment the invention 10 includes an isolated polypeptide comprising a fragment of the polypeptide of sufficient length to represent a sequence unique within the human genome and identifying a polypeptide that is a human cancer associated antigen precursor.

According to another aspect of the invention a kit for detecting the presence of the expression of a cancer associated antigen precursor is provided. The kit includes a pair of 15 isolated nucleic acid molecules each of which consists essentially of a molecule selected from the group consisting of (a) a 12-32 nucleotide contiguous segment of the nucleotide sequence of any of the NA Group 1 molecules and (b) complements of ("a"), wherein the contiguous segments are nonoverlapping. In one embodiment the pair of isolated nucleic acid molecules is constructed and arranged to selectively amplify an isolated nucleic acid molecule that is a 20 NA Group 3 molecule. Preferably, the pair amplifies a human NA Group 3 molecule.

According to another aspect of the invention a method for treating a subject with a disorder characterized by expression of a human cancer associated antigen precursor is provided. The method includes the step of administering to the subject an amount of an agent, which enriches selectively in the subject the presence of complexes of an HLA molecule and a 25 human cancer associated antigen, effective to ameliorate the disorder, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule comprising NA group 1 nucleic acid molecules, (b) a nucleic acid molecule comprising NA group 3 nucleic acid molecules, (c) a nucleic acid molecule comprising NA 30 group 5 nucleic acid molecules.

In one embodiment the disorder is characterized by expression of a plurality of human cancer associated antigen precursors and wherein the agent is a plurality of agents, each of which enriches selectively in the subject the presence of complexes of an HLA molecule and a

different human cancer associated antigen. Preferably the plurality is at least 2, at least 3, at least 4, or at least 5 such agents.

In another embodiment the agent is an isolated polypeptide selected from the group consisting of PP Group 1, PP Group 2, PP Group 3, PP Group 4, and PP group 5 polypeptides.

In yet another embodiment the disorder is cancer.

According to another aspect the invention is a method for treating a subject having a condition characterized by expression of a cancer associated antigen precursor in cells of the subject. The method includes the steps of (i) removing an immunoreactive cell containing sample from the subject, (ii) contacting the immunoreactive cell containing sample to the host cell under conditions favoring production of cytolytic T cells against a human cancer associated antigen which is a fragment of the precursor, (iii) introducing the cytolytic T cells to the subject in an amount effective to lyse cells which express the human cancer associated antigen, wherein the host cell is transformed or transfected with an expression vector comprising an isolated nucleic acid molecule operably linked to a promoter, the isolated nucleic acid molecule being selected from the group of nucleic acid molecules consisting of NA Group 1, NA Group 2, NA Group 3, NA Group 4, NA Group 5.

In one embodiment the host cell recombinantly expresses an HLA molecule which binds the human cancer associated antigen. In another embodiment the host cell endogenously expresses an HLA molecule which binds the human cancer associated antigen.

The invention includes in another aspect a method for treating a subject having a condition characterized by expression of a cancer associated antigen precursor in cells of the subject. The method includes the steps of (i) identifying a nucleic acid molecule expressed by the cells associated with said condition, wherein said nucleic acid molecule is a NA Group 1 molecule (ii) transfecting a host cell with a nucleic acid selected from the group consisting of (a) the nucleic acid molecule identified, (b) a fragment of the nucleic acid identified which includes a segment coding for a cancer associated antigen, (c) deletions, substitutions or additions to (a) or (b), and (d) degenerates of (a), (b), or (c); (iii) culturing said transfected host cells to express the transfected nucleic acid molecule, and; (iv) introducing an amount of said host cells or an extract thereof to the subject effective to increase an immune response against the cells of the subject associated with the condition. Preferably, the antigen is a human antigen and the subject is a human.

In one embodiment the method also includes the step of (a) identifying an MHC

molecule which presents a portion of an expression product of the nucleic acid molecule, wherein the host cell expresses the same MHC molecule as identified in (a) and wherein the host cell presents an MHC binding portion of the expression product of the nucleic acid molecule.

5 In another embodiment the method also includes the step of treating the host cells to render them non-proliferative.

In yet another embodiment the immune response comprises a B-cell response or a T cell response. Preferably the response is a T-cell response which comprises generation of cytolytic T-cells specific for the host cells presenting the portion of the expression product of 10 the nucleic acid molecule or cells of the subject expressing the human cancer associated antigen.

In another embodiment the nucleic acid molecule is a NA Group 3 molecule.

Another aspect of the invention is a method for treating or diagnosing or monitoring a subject having a condition characterized by expression of an abnormal amount of a protein 15 encoded by a nucleic acid molecule that is a NA Group 1 molecule. The method includes the step of administering to the subject an antibody which specifically binds to the protein or a peptide derived therefrom, the antibody being coupled to a therapeutically useful agent, in an amount effective to treat the condition.

In one embodiment the antibody is a monoclonal antibody. Preferably the monoclonal 20 antibody is a chimeric antibody or a humanized antibody.

In another aspect the invention is a method for treating a condition characterized by expression in a subject of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule. The method involves the step of administering to a subject at least one of the pharmaceutical compositions of the invention described above in 25 an amount effective to prevent, delay the onset of, or inhibit the condition in the subject. In one embodiment the condition is cancer. In another embodiment the method includes the step of first identifying that the subject expresses in a tissue abnormal amounts of the protein.

The invention in another aspect is a method for treating a subject having a condition characterized by expression of abnormal amounts of a protein encoded by a nucleic acid 30 molecule that is a NA Group 1 nucleic acid molecule. The method includes the steps of (i) identifying cells from the subject which express abnormal amounts of the protein; (ii) isolating a sample of the cells; (iii) cultivating the cells, and (iv) introducing the cells to the subject in an amount effective to provoke an immune response against the cells.

In one embodiment the method includes the step of rendering the cells non-proliferative, prior to introducing them to the subject.

In another aspect the invention is a method for treating a pathological cell condition characterized by abnormal expression of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule. The method includes the step of administering to a subject in need thereof an effective amount of an agent which inhibits the expression or activity of the protein.

In one embodiment the agent is an inhibiting antibody which selectively binds to the protein and wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or a fragment thereof. In another embodiment the agent is an antisense nucleic acid molecule which selectively binds to the nucleic acid molecule which encodes the protein. In yet another important embodiment the nucleic acid molecule is a NA Group 3 nucleic acid molecule.

The invention includes in another aspect a composition of matter useful in stimulating an immune response to a plurality of proteins encoded by nucleic acid molecules that are NA Group 1 molecules. The composition is a plurality of peptides derived from the amino acid sequences of the proteins, wherein the peptides bind to one or more MHC molecules presented on the surface of the cells which express an abnormal amount of the protein.

In one embodiment at least a portion of the plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto. In another embodiment the composition of matter includes an adjuvant. In another embodiment the adjuvant is a saponin, GM-CSF, or an interleukin. In still another embodiment, the compositions also includes at least one peptide useful in stimulating an immune response to at least one protein which is not encoded by nucleic acid molecules that are NA Group 1 molecules, wherein the at least one peptide binds to one or more MHC molecules.

According to another aspect the invention is an isolated antibody which selectively binds to a complex of: (i) a peptide derived from a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule and (ii) and an MHC molecule to which binds the peptide to form the complex, wherein the isolated antibody does not bind to (i) or (ii) alone.

In one embodiment the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody or a fragment thereof.

In certain embodiments of the foregoing method and compositions, preferred peptides include peptides having the amino acid sequences set forth in SEQ ID NOs:11-15, particularly

SEQ ID NO:14. In other embodiments, functional variants of the peptides are used.

The invention also involves the use of the genes, gene products, fragments thereof, agents which bind thereto, and so on in the preparation of medicaments. A particular medicament is for treating cancer and a more particular medicament is for treating breast cancer, renal cancer, T cell leukemia, colon cancer, head & neck cancer and/or ovarian cancer.

In certain embodiments, it may be preferred that the methods described above are not practiced using some of the genes, gene products, fragments thereof, and/or agents which bind thereto on one or more of the following cancerous tissues: kidney cancer, adrenal adenoma, colon adenocarcinoma, pancreatic carcinoma, uterus adenocarcinoma, germ cell tumor, colon adenocarcinoma, ovarian cancer, Wilms tumor, squamous cell carcinoma, glioblastoma, anaplastic oligodendroglioma, , B-cell chronic lymphotic leukemia, larynx, germinal center B cell and breast tumors.

Still other embodiments and aspects of the invention will become apparent in connection with the description of the invention which follows.

Detailed Description of the Invention

In the above summary and in the ensuing description, lists of sequences are provided. The lists are meant to embrace each single sequence separately, two or more sequences together where they form a part of the same gene, any combination of two or more sequences which relate to different genes, including and up to the total number on the list, as if each and every combination were separately and specifically enumerated. Likewise, when mentioning fragment size, it is intended that a range embrace the smallest fragment mentioned to the full-length of the sequence (less one nucleotide or amino acid so that it is a fragment), each and every fragment length intended as if specifically enumerated. Thus, if a fragment could be between 10 and 15 in length, it is explicitly meant to mean 10, 11, 12, 13, 14, or 15 in length.

The summary and the claims mention antigen precursors and antigens. As used in the summary and in the claims, a precursor is substantially the full-length protein encoded by the coding region of the isolated DNA and the antigen is a peptide which complexes with MHC, preferably HLA, and which participates in the immune response as part of that complex. Such antigens are typically 9 amino acids long, although this may vary slightly.

As used herein, a subject is a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent. In all embodiments human cancer antigens and human subjects are preferred. The present invention in one aspect involves the cloning of cDNAs encoding

human cancer associated antigen precursors using autologous antisera of subjects having breast cancer and T cell leukemia. The sequences of the clones representing genes identified according to the methods described herein are presented in the attached Sequence Listing. Of the foregoing, it can be seen that some of the clones are considered completely novel as no coding regions were found in the databases searched. Other clones are novel but have some nucleotide or amino acid homologies to sequences deposited in databases (mainly EST sequences). Nevertheless, the entire gene sequence was not previously known. In some cases no function was suspected and in other cases, even if a function was suspected, it was not known that the gene was associated with cancer. In all cases, it was not known or suspected that the gene encoded a cancer antigen which reacted with antibody from autologous sera. Analysis of the clone sequences by comparison to nucleic acid and protein databases determined that still other of the clones surprisingly are closely related to other previously-cloned genes. The sequences of these related genes is also presented in the Sequence Listing. The nature of the foregoing genes as encoding antigens recognized by the immune systems of cancer patients is, of course, unexpected.

The invention thus involves in one aspect cancer associated antigen polypeptides, genes encoding those polypeptides, functional modifications and variants of the foregoing, useful fragments of the foregoing, as well as diagnostics and therapeutics relating thereto.

Homologs and alleles of the cancer associated antigen nucleic acids of the invention can be identified by conventional techniques. Thus, an aspect of the invention is those nucleic acid sequences which code for cancer associated antigen precursors. Because this application contains so many sequences, the following chart is provided to identify the various groups of sequences discussed in the claims and in the summary:

Nucleic Acid Sequences

NA Group 1. (a) nucleic acid molecules which hybridize under stringent conditions to a molecule consisting of a nucleic acid sequence selected from the group consisting of nucleic acid sequences among SEQ ID NOs: 1, 3, 4, 6, 7, 9 and 16, and which code for a cancer associated antigen precursor,

(b) deletions, additions and substitutions which code for a respective cancer associated antigen precursor,

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or

(b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

NA Group 2. Fragments of NA Group 1, which codes for a polypeptide which, or a portion of which, binds an MHC molecule to form a complex recognized by an autologous antibody or lymphocyte.

NA Group 3. The subset of NA Group 1 where the nucleotide sequence is selected from the group consisting of:

(a) previously unknown human nucleic acids coding for a human cancer associated antigen precursor,

(b) deletions, additions and substitutions which code for a respective human cancer associated antigen precursor,

(c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and

(d) complements of (a), (b) or (c).

NA Group 4. Fragments of NA Group 3, which code for a polypeptide which, or a portion of which, binds to an MHC molecule to form a complex recognized by an autologous antibody or lymphocyte.

NA Group 5. A subset of NA Group 1, comprising human cancer associated antigens that react with allogeneic cancer antisera.

Polypeptide Sequences

PP Group 1. Polypeptides encoded by NA Group 1.

PP Group 2. Polypeptides encoded by NA Group 2

PP Group 3. Polypeptides encoded by NA Group 3.

PP Group 4. Polypeptides encoded by NA Group 4.

PP Group 5. Polypeptides encoded by NA Group 5.

The term “stringent conditions” as used herein refers to parameters with which the art

is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons,
5 Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH_2PO_4(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane
10 upon which the DNA is transferred is washed, for example, in 2 x SSC at room temperature and then at 0.1 - 0.5 x SSC/0.1 x SDS at temperatures up to 68°C.

There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be
15 able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of cancer associated antigen nucleic acids of the invention (e.g., by using lower stringency conditions). The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

20 In general homologs and alleles typically will share at least 80% nucleotide identity and/or at least 90% amino acid identity to the sequences of cancer associated antigen nucleic acid and polypeptides, respectively, in some instances will share at least 90% nucleotide identity and/or at least 95% amino acid identity and in still other instances will share at least 95% nucleotide identity and/or at least 99% amino acid identity. The homology can be
25 calculated using various, publicly available software tools developed by National Center for Biotechnology Information (Bethesda, Maryland) that can be obtained through the Internet (ftp:/ncbi.nlm.nih.gov/pub/). Exemplary tools include the BLAST system available at http://www.ncbi.nlm.nih.gov, preferably using default settings. Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be
30 obtained using the MacVector sequence analysis software (Oxford Molecular Group). Watson-Crick complements of the foregoing nucleic acids also are embraced by the invention.

Alleles, for example, include the genes which encode HOM-TALL1-5 and MO-BC-203 clones. As disclosed herein, these clones are isolated from different individuals but share

about 95-99% nucleotide identity in their regions of overlap. Thus these clones likely represent allelic variants of the same gene present in different individuals. Allelic variants, such as these, of the nucleic acid molecules (and polypeptides) disclosed herein are embraced by the invention.

5 In screening for cancer associated antigen genes, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal. In screening for the expression of cancer associated antigen nucleic acids, Northern blot hybridizations using the foregoing conditions can be 10 performed on samples taken from breast cancer and/or T cell leukemia patients or subjects suspected of having a condition characterized by expression of the cancer associated antigen genes disclosed herein. Amplification protocols such as polymerase chain reaction using primers which hybridize to the sequences presented also can be used for detection of the cancer associated antigen genes or expression thereof.

15 The breast cancer, T cell leukemia and/or ovarian cancer associated genes correspond to SEQ ID NOs:1, 3, 4, 6, 7, 9 and 16. The preferred breast cancer and/or T cell leukemia associated antigens for the methods of diagnosis disclosed herein are those which were found to react with allogeneic cancer antisera (i.e. NA Group 5). Encoded polypeptides (e.g., proteins), peptides and antisera thereto are also preferred for diagnosis.

20 As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained 25 in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the 30 material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

As used herein with respect to polypeptides, "isolated" means separated from its native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may, but need not be, substantially pure. The term "substantially pure" means that the proteins or polypeptides are essentially free of other substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating cancer associated antigen polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides. In preferred embodiments, these modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as antigenicity, enzymatic activity, receptor binding, formation of complexes by binding of peptides by MHC class I and class II molecules, etc. In certain embodiments, the modified

nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

For example, modified nucleic acid molecules which encode polypeptides having single amino acid changes can be prepared. Each of these nucleic acid molecules can have one, two or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on. In the foregoing example, each combination of two amino acids is included in the set of modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions. Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.

The invention also provides isolated unique fragments of cancer associated antigen nucleic acid sequences or complements thereof. A unique fragment is one that is a 'signature' for the larger nucleic acid. It, for example, is long enough to assure that its precise sequence is not found in molecules within the human genome outside of the cancer associated antigen nucleic acids defined above (and human alleles). Those of ordinary skill in the art may apply no more than routine procedures to determine if a fragment is unique within the human genome. Unique fragments, however, exclude fragments completely composed of the nucleotide sequences of any of GenBank accession numbers listed in Table 4 or other previously published sequences as of the filing date of the priority documents for sequences listed in a respective priority document or the filing date of this application for sequences listed for the first time in this application which overlap the sequences of the invention.

A fragment which is completely composed of the sequence described in the foregoing GenBank deposits is one which does not include any of the nucleotides unique to the sequences of the invention. Thus, a unique fragment must contain a nucleotide sequence other than the exact sequence of those in GenBank or fragments thereof. The difference may be an addition, deletion or substitution with respect to the GenBank sequence or it may be a sequence wholly separate from the GenBank sequence.

Unique fragments can be used as probes in Southern and Northern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200, 250, 300 or more nucleotides are preferred for certain uses such as Southern and Northern blots, while smaller fragments will be preferred for uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments, or for generating immunoassay components. Likewise, unique fragments can be employed to produce nonfused fragments of the cancer associated antigen polypeptides, useful, for example, in the preparation of antibodies, and in immunoassays. Unique fragments further can be used as antisense molecules to inhibit the expression of cancer associated antigen nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of cancer associated antigen sequences and complements thereof will require longer segments to be unique while others will require only short segments, typically between 12 and 32 nucleotides (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 or more bases long, up to the entire length of the disclosed sequence. As mentioned above, this disclosure intends to embrace each and every fragment of each sequence, beginning at the first nucleotide, the second nucleotide and so on, up to 8 nucleotides short of the end, and ending anywhere from nucleotide number 8, 9, 10 and so on for each sequence, up to the very last nucleotide (provided the sequence is unique as described above).

Virtually any segment of the polypeptide coding region of novel cancer associated antigen nucleic acids, or complements thereof, that is 25 or more nucleotides in length will be unique. Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from other sequences in the human genome of the fragment to those on

known databases typically is all that is necessary, although *in vitro* confirmatory hybridization and sequencing analysis may be performed.

Especially preferred include nucleic acids encoding a series of epitopes, known as "polytopes". The epitopes can be arranged in sequential or overlapping fashion (*see, e.g.*, Thomson et al., *Proc. Natl. Acad. Sci. USA* 92:5845-5849, 1995; Gilbert et al., *Nature Biotechnol.* 15:1280-1284, 1997), with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired. The polytope is processed to generated individual epitopes which are recognized by the immune system for generation of immune responses.

Thus, for example, peptides derived from a polypeptide having an amino acid sequence encoded by one of the nucleic acid disclosed herein (such as the peptides having SEQ ID NOs:11, 12, 13, 14 and 15), and which are presented by MHC molecules and recognized by CTL or T helper lymphocytes, can be combined with peptides from one or more other cancer associated antigens (e.g. by preparation of hybrid nucleic acids or polypeptides) to form "polytopes". The two or more peptides (or nucleic acids encoding the peptides) can be selected from those described herein, or they can include one or more peptides of previously known cancer associated antigens. Exemplary cancer associated peptide antigens that can be administered to induce or enhance an immune response are derived from tumor associated genes and encoded proteins including MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A7, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-A12, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, GAGE-9, BAGE-1, RAGE-1, LB33/MUM-1, PRAME, NAG, MAGE-B2, MAGE-B3, MAGE-B4, tyrosinase, brain glycogen phosphorylase, Melan-A, MAGE-C1 MAGE-C2, MAGE-C3, MAGE-C4, MAGE-C5, NY-ESO-1, LAGE-1, SSX-1, SSX-2 (HOM-MEL-40), SSX-4, SSX-5, SCP-1 and CT-7. See, for example, PCT application publication no. WO96/10577. Other examples will be known to one of ordinary skill in the art (for example, see Coulie, *Stem Cells* 13:393-403, 1995), and can be used in the invention in a like manner as those disclosed herein. One of ordinary skill in the art can prepare polypeptides comprising one or more peptides and one or more of the foregoing cancer associated peptides, or nucleic acids encoding such polypeptides, according to standard procedures of molecular biology.

Thus polytopes are groups of two or more potentially immunogenic or immune response stimulating peptides which can be joined together in various arrangements (e.g.

concatenated, overlapping). The polytope (or nucleic acid encoding the polytope) can be administered in a standard immunization protocol, e.g. to animals, to test the effectiveness of the polytope in stimulating, enhancing and/or provoking an immune response.

The peptides can be joined together directly or via the use of flanking sequences to form polytopes, and the use of polytopes as vaccines is well known in the art (see, e.g., Thomson et al., *Proc. Acad. Natl. Acad. Sci USA* 92(13):5845-5849, 1995; Gilbert et al., *Nature Biotechnol.* 15(12):1280-1284, 1997; Thomson et al., *J. Immunol.* 157(2):822-826, 1996; Tam et al., *J. Exp. Med.* 171(1):299-306, 1990). For example, Tam showed that polytopes consisting of both MHC class I and class II binding epitopes successfully generated antibody and protective immunity in a mouse model. Tam also demonstrated that polytopes comprising "strings" of epitopes are processed to yield individual epitopes which are presented by MHC molecules and recognized by CTLs. Thus polytopes containing various numbers and combinations of epitopes can be prepared and tested for recognition by CTLs and for efficacy in increasing an immune response.

It is known that tumors express a set of tumor antigens, of which only certain subsets may be expressed in the tumor of any given patient. Polytopes can be prepared which correspond to the different combination of epitopes representing the subset of tumor rejection antigens expressed in a particular patient. Polytopes also can be prepared to reflect a broader spectrum of tumor rejection antigens known to be expressed by a tumor type. Polytopes can be introduced to a patient in need of such treatment as polypeptide structures, or via the use of nucleic acid delivery systems known in the art (see, e.g., Allsopp et al., *Eur. J. Immunol.* 26(8):1951-1959, 1996). Adenovirus, pox virus, Ty-virus like particles, adeno-associated virus, plasmids, bacteria, etc. can be used in such delivery. One can test the polytope delivery systems in mouse models to determine efficacy of the delivery system. The systems also can be tested in human clinical trials.

In instances in which a human HLA class I molecule presents tumor rejection antigens derived from cancer associated nucleic acids, the expression vector may also include a nucleic acid sequence coding for the HLA molecule that presents any particular tumor rejection antigen derived from these nucleic acids and polypeptides. Alternatively, the nucleic acid sequence coding for such a HLA molecule can be contained within a separate expression vector. In a situation where the vector contains both coding sequences, the single vector can be used to transfect a cell which does not normally express either one. Where the coding sequences for a cancer associated antigen precursor and the HLA molecule which presents it

are contained on separate expression vectors, the expression vectors can be cotransfected. The cancer associated antigen precursor coding sequence may be used alone, when, e.g. the host cell already expresses a HLA molecule which presents a cancer associated antigen derived from precursor molecules. Of course, there is no limit on the particular host cell 5 which can be used. As the vectors which contain the two coding sequences may be used in any antigen-presenting cells if desired, and the gene for cancer associated antigen precursor can be used in host cells which do not express a HLA molecule which presents a cancer associated antigen. Further, cell-free transcription systems may be used in lieu of cells.

As mentioned above, the invention embraces antisense oligonucleotides that 10 selectively bind to a nucleic acid molecule encoding a cancer associated antigen polypeptide, to reduce the expression of cancer associated antigens. This is desirable in virtually any medical condition wherein a reduction of expression of cancer associated antigens is desirable, e.g., in the treatment of cancer. This is also useful for *in vitro* or *in vivo* testing of the effects of a reduction of expression of one or more cancer associated antigens.

15 As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that 20 mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It 25 is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon the sequences of nucleic acids encoding breast cancer and/or T cell leukemia associated antigen, or upon allelic or homologous genomic and/or cDNA sequences, 30 one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. For example, a "gene walk" comprising a series of oligonucleotides of 15-30 nucleotides spanning the length of a cancer associated antigen can be prepared, followed by testing for inhibition of cancer

associated antigen expression. Optionally, gaps of 5-10 nucleotides can be left between the oligonucleotides to reduce the number of oligonucleotides synthesized and tested.

In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although the listed sequences are cDNA sequences, one of ordinary skill in the art may easily derive the genomic DNA corresponding to the cDNA of a cancer associated antigen. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the genomic DNA corresponding to nucleic acids encoding cancer associated antigens. Similarly, antisense to allelic or homologous cDNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in

which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamidates, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding breast cancer and/or T cell leukemia associated antigen polypeptides, together with pharmaceutically acceptable carriers.

Antisense oligonucleotides may be administered as part of a pharmaceutical composition. Such a pharmaceutical composition may include the antisense oligonucleotides in combination with any standard physiologically and/or pharmaceutically acceptable carriers which are known in the art. The compositions should be sterile and contain a therapeutically effective amount of the antisense oligonucleotides in a unit of weight or volume suitable for administration to a patient. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art, as further described below.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA

although RNA vectors are also available. Vectors include, but are not limited to, plasmids, phagemids and virus genomes. A cloning vector is one which is able to replicate autonomously or integrated in the genome in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., ß-galactosidase, luciferase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribed and 5' non-translated sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribed regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a cancer associated antigen polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pcDNA3.1 and pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr Virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1α, which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the adenovirus as an Adeno.P1A recombinant for the expression of an antigen is disclosed by Warnier et al., in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996). Additional vectors for delivery of nucleic acid are provided below.

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of a vector and one or more of the previously discussed cancer associated antigen nucleic acid molecules. Other components may be added, as desired, as long as the previously mentioned nucleic acid molecules, which are required, are included. The invention also includes kits for amplification of a cancer associated antigen nucleic acid, including at least one pair of amplification primers which hybridize to a cancer associated antigen nucleic acid. The primers preferably are 12-32 nucleotides in length and are non-overlapping to prevent formation of "primer-dimers". One of the primers will hybridize to one strand of the cancer associated antigen nucleic acid and the second primer will hybridize to the complementary strand of the cancer associated antigen nucleic acid, in an arrangement which permits amplification of the cancer associated antigen nucleic acid. Selection of appropriate primer pairs is standard in the art. For example, the selection can be made with assistance of a computer program designed for such a purpose, optionally followed by testing the primers for amplification specificity and efficiency.

The invention also permits the construction of cancer associated antigen gene "knock-outs" and transgenic overexpression in cells and in animals, providing materials for studying certain aspects of cancer and immune system responses to cancer.

The invention also provides isolated polypeptides (including whole proteins and partial proteins) encoded by the foregoing cancer associated antigen nucleic acids. Such polypeptides are useful, for example, alone or as fusion proteins to generate antibodies, as components of an immunoassay or diagnostic assay or as therapeutics. Cancer associated antigen polypeptides can be isolated from biological samples including tissue or cell homogenates, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Short polypeptides, including antigenic peptides (such as are presented by MHC molecules on the surface of a cell for immune recognition) also can be synthesized chemically using well-established methods of peptide synthesis.

A unique fragment of a cancer associated antigen polypeptide, in general, has the features and characteristics of unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon factors such as whether the fragment constitutes a portion of a conserved protein

domain. Thus, some regions of cancer associated antigens will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 or 12 or more amino acids including each integer up to the full length).

5 Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a unique fragment of a polypeptide include interaction with antibodies, interaction with other polypeptides or fragments thereof, selective binding of nucleic acids or proteins, and enzymatic activity. One important activity is the ability to act as a signature for identifying 10 the polypeptide. Another is the ability to complex with HLA and to provoke in a human an immune response. Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known databases typically is all that is necessary.

15 The invention embraces variants of the cancer associated antigen polypeptides described above. As used herein, a "variant" of a cancer associated antigen polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a cancer associated antigen polypeptide. Modifications which create a cancer associated antigen variant can be made to a cancer associated antigen polypeptide 1) to reduce or 20 eliminate an activity of a cancer associated antigen polypeptide; 2) to enhance a property of a cancer associated antigen polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 3) to provide a novel activity or property to a cancer associated antigen polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 4) to provide equivalent or better binding to an HLA molecule. 25 Modifications to a cancer associated antigen polypeptide are typically made to the nucleic acid which encodes the cancer associated antigen polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as 30 biotin, addition of a fatty acid, substitution of L-amino acids with D-amino acids, and the like. Modifications also embrace fusion proteins comprising all or part of the cancer associated antigen amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus

"design" a variant cancer associated antigen polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary a only a portion of the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a cancer associated antigen polypeptide can be proposed and tested to determine whether the variant retains a desired conformation. Other computational and computer modeling methods for designing polypeptide mimetics which retain activity of the polypeptides described herein, as well as selection methods such as phage display of peptide libraries are known in the art.

In general, variants include cancer associated antigen polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its desired physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a cancer associated antigen polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a cancer associated antigen polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such a hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant cancer associated antigen polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a cancer associated antigen gene or cDNA clone to enhance expression of the polypeptide. The activity of variants of cancer associated antigen polypeptides can be tested by cloning the gene encoding the variant cancer associated antigen polypeptide into a bacterial or mammalian expression vector, introducing the vector into an

appropriate host cell, expressing the variant cancer associated antigen polypeptide, and testing for a functional capability of the cancer associated antigen polypeptides as disclosed herein. For example, the variant cancer associated antigen polypeptide can be tested for reaction with autologous or allogeneic sera as disclosed in the Examples. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art.

The skilled artisan will also realize that conservative amino acid substitutions may be made in cancer associated antigen polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e, the variants retain the functional capabilities of the cancer associated antigen polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the cancer associated antigen polypeptides include conservative amino acid substitutions of in the amino acid sequences of proteins disclosed herein. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

For example, upon determining that a peptide derived from a cancer associated antigen polypeptide is presented by an MHC molecule and recognized by CTLs (e.g., as described in the Examples), one can make conservative amino acid substitutions to the amino acid sequence of the peptide, particularly at residues which are thought not to be direct contact points with the MHC molecule. For example, methods for identifying functional variants of HLA class II binding peptides are provided in a published PCT application of Strominger and Wucherpfennig (PCT/US96/03182). Peptides bearing one or more amino acid substitutions also can be tested for concordance with known HLA/MHC motifs prior to synthesis using, e.g. the computer program described by D'Amaro and Drijfhout (D'Amaro et al., *Human Immunol.* 43:13-18, 1995; Drijfhout et al., *Human Immunol.* 43:1-12, 1995). The substituted peptides can then be tested for binding to the MHC molecule and recognition by CTLs when

bound to MHC. These variants can be tested for improved stability and are useful, *inter alia*, in vaccine compositions.

Conservative amino-acid substitutions in the amino acid sequence of cancer associated antigen polypeptides to produce functionally equivalent variants of cancer associated antigen polypeptides typically are made by alteration of a nucleic acid encoding a cancer associated antigen polypeptide. Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a cancer associated antigen polypeptide. Where amino acid substitutions are made to a small unique fragment of a cancer associated antigen polypeptide, such as an antigenic epitope recognized by autologous or allogeneic sera or cytolytic T lymphocytes (e.g., SEQ ID NOs:11-15), the substitutions can be made by directly synthesizing the peptide. The activity of functionally equivalent fragments of cancer associated antigen polypeptides can be tested by cloning the gene encoding the altered cancer associated antigen polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered cancer associated antigen polypeptide, and testing for a functional capability of the cancer associated antigen polypeptides as disclosed herein. Peptides which are chemically synthesized can be tested directly for function, e.g., for binding to antisera recognizing associated antigens.

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of the cancer associated antigen protein molecules. A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated cancer associated antigen molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce polypeptide. Those skilled in the art also can readily follow known methods for isolating cancer associated antigen polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The isolation and identification of cancer associated antigen genes also makes it possible for the artisan to diagnose a disorder characterized by expression of cancer associated antigens. These methods involve determining expression of one or more cancer associated antigen nucleic acids, and/or encoded cancer associated antigen polypeptides and/or peptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes. In the latter situation, such determinations can be carried out by screening patient antisera for recognition of the polypeptide.

The invention also makes it possible isolate proteins which bind to cancer associated antigens as disclosed herein, including antibodies and cellular binding partners of the cancer associated antigens. Additional uses are described further herein.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from cancer associated antigen polypeptides. A dominant negative polypeptide is an inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative catalytically-inactive kinase which interacts normally with target proteins but does not phosphorylate the target proteins can reduce phosphorylation of the target proteins in response to a cellular signal. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, given the teachings contained herein of breast cancer and T cell leukemia associated antigens, especially those which are similar to known proteins which have known activities, one of ordinary skill in the art can modify the sequence of the cancer associated antigens by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory*

Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

5 The invention also involves agents such as polypeptides which bind to cancer associated antigen polypeptides. Such binding agents can be used, for example, in screening assays to detect the presence or absence of cancer associated antigen polypeptides and complexes of cancer associated antigen polypeptides and their binding partners and in purification protocols to isolated cancer associated antigen polypeptides and complexes of 10 cancer associated antigen polypeptides and their binding partners. Such agents also can be used to inhibit the native activity of the cancer associated antigen polypeptides, for example, by binding to such polypeptides.

The invention, therefore, embraces peptide binding agents which, for example, can be antibodies or fragments of antibodies having the ability to selectively bind to cancer 15 associated antigen polypeptides. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & 20 Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an $F(ab')_2$ fragment, retains both of the antigen binding sites of an intact antibody. Similarly, 25 an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may 30 be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of

the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3).
5 The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly
10 manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. See, e.g., U.S. patents 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205.

Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the
15 murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for $F(ab')_2$, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR
20 and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric $F(ab')_2$ fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by
25 homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies.

Thus, the invention involves polypeptides of numerous size and type that bind specifically to cancer associated antigen polypeptides, and complexes of both cancer
30 associated antigen polypeptides and their binding partners. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also

can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array. One then can select phage-bearing inserts which bind to the cancer associated antigen polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the cancer associated antigen polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the cancer associated antigen polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the cancer associated antigen polypeptides. Thus, the cancer associated antigen polypeptides of the invention, or a fragment thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the cancer associated antigen polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of cancer associated antigen and for other purposes that will be apparent to those of ordinary skill in the art.

As detailed herein, the foregoing antibodies and other binding molecules may be used for example to identify tissues expressing protein or to purify protein. Antibodies also may be coupled to specific diagnostic labeling agents for imaging of cells and tissues that express cancer associated antigens or to therapeutically useful agents according to standard coupling procedures. Diagnostic agents include, but are not limited to, barium sulfate, iocetamic acid, iopanoic acid, ipodate calcium, diatrizoate sodium, diatrizoate meglumine, metrizamide, tyropanoate sodium and radiodiagnostics including positron emitters such as fluorine-18 and carbon-11, gamma emitters such as iodine-123, technetium-99m, iodine-131 and indium-111, and nuclides for nuclear magnetic resonance such as fluorine and gadolinium. Other diagnostic agents useful in the invention will be apparent to one of ordinary skill in the art. As used herein, "therapeutically useful agents" include any therapeutic molecule which

desirably is targeted selectively to a cell expressing one of the cancer antigens disclosed herein, including antineoplastic agents, radioiodinated compounds, toxins, other cytostatic or cytolytic drugs, and so forth. Antineoplastic therapeutics are well known and include: aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabidine, dacarbazine, dactinomycin, daunorubicin, doxorubicin, taxol, etoposide, fluorouracil, interferon-α, lomustine, mercaptopurine, methotrexate, mitotane, procarbazine HCl, thioguanine, vinblastine sulfate and vincristine sulfate. Additional antineoplastic agents include those disclosed in Chapter 52, Antineoplastic Agents (Paul Calabresi and Bruce A. Chabner), and the introduction thereto, 1202-1263, of Goodman and Gilman's "The Pharmacological Basis of Therapeutics", Eighth Edition, 1990, McGraw-Hill, Inc. (Health Professions Division). Toxins can be proteins such as, for example, pokeweed anti-viral protein, cholera toxin, pertussis toxin, ricin, gelonin, abrin, diphtheria exotoxin, or *Pseudomonas* exotoxin. Toxin moieties can also be high energy-emitting radionuclides such as cobalt-60.

In the foregoing methods and compositions, antibodies prepared according to the invention also preferably are specific for the cancer associated antigen/MHC complexes described herein.

When "disorder" is used herein, it refers to any pathological condition where the cancer associated antigens are expressed. An example of such a disorder is cancer, including breast cancer, renal cancer and leukemia as particular examples.

Samples of tissue and/or cells for use in the various methods described herein can be obtained through standard methods such as tissue biopsy, including punch biopsy and cell scraping, and collection of blood or other bodily fluids by aspiration or other methods.

In certain embodiments of the invention, an immunoreactive cell sample is removed from a subject. By "immunoreactive cell" is meant a cell which can mature into an immune cell (such as a B cell, a helper T cell, or a cytolytic T cell) upon appropriate stimulation. Thus immunoreactive cells include $CD34^+$ hematopoietic stem cells, immature T cells and immature B cells. When it is desired to produce cytolytic T cells which recognize a cancer associated antigen, the immunoreactive cell is contacted with a cell which expresses a cancer associated antigen under conditions favoring production, differentiation and/or selection of cytolytic T cells; the differentiation of the T cell precursor into a cytolytic T cell upon exposure to antigen is similar to clonal selection of the immune system.

Some therapeutic approaches based upon the disclosure are premised on a response by

a subject's immune system, leading to lysis of antigen presenting cells, such as breast cancer and/or T cell leukemia cells which present one or more cancer associated antigens. One such approach is the administration of autologous CTLs specific to a cancer associated antigen/MHC complex to a subject with abnormal cells of the phenotype at issue. It is within
5 the ability of one of ordinary skill in the art to develop such CTLs *in vitro*. An example of a method for T cell differentiation is presented in International Application number PCT/US96/05607. Generally, a sample of cells taken from a subject, such as blood cells, are contacted with a cell presenting the complex and capable of provoking CTLs to proliferate. The target cell can be a transfectant, such as a COS cell. These transfectants present the
10 desired complex at their surface and, when combined with a CTL of interest, stimulate its proliferation. COS cells are widely available, as are other suitable host cells. Specific production of CTL clones is well known in the art. The clonally expanded autologous CTLs then are administered to the subject.

CTL proliferation can be increased by increasing the level of tryptophan in T cell
15 cultures, by inhibiting enzymes which catabolizes tryptophan, such as indoleamine 2,3-dioxygenase (IDO), or by adding tryptophan to the culture. Proliferation of T cells is enhanced increasing the rate of proliferation and/or extending the number of divisions of the T cells in culture. In addition, increasing tryptophan in T cell cultures also enhances the lytic activity of the T cells grown in culture.

20 Another method for selecting antigen-specific CTL clones has recently been described (Altman et al., *Science* 274:94-96, 1996; Dunbar et al., *Curr. Biol.* 8:413-416, 1998), in which fluorogenic tetramers of MHC class I molecule/peptide complexes are used to detect specific CTL clones. Briefly, soluble MHC class I molecules are folded *in vitro* in the presence of β_2-microglobulin and a peptide antigen which binds the class I molecule. After purification, the
25 MHC/peptide complex is purified and labeled with biotin. Tetramers are formed by mixing the biotinylated peptide-MHC complex with labeled avidin (e.g. phycoerythrin) at a molar ratio or 4:1. Tetramers are then contacted with a source of CTLs such as peripheral blood or lymph node. The tetramers bind CTLs which recognize the peptide antigen/MHC class I complex. Cells bound by the tetramers can be sorted by fluorescence activated cell sorting to
30 isolate the reactive CTLs. The isolated CTLs then can be expanded *in vitro* for use as described herein.

To detail a therapeutic methodology, referred to as adoptive transfer (Greenberg, *J. Immunol.* 136(5): 1917, 1986; Riddel et al., *Science* 257: 238, 1992; Lynch et al, *Eur. J.*

Immunol. 21: 1403-1410,1991; Kast et al., *Cell* 59: 603-614, 1989), cells presenting the desired complex (e.g., dendritic cells) are combined with CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterized by certain of the abnormal cells presenting the
5 particular complex. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal.

The foregoing therapy assumes that at least some of the subject's abnormal cells present the relevant HLA/cancer associated antigen complex. This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular
10 HLA molecule, as well as how to identify cells expressing DNA of the pertinent sequences, in this case a cancer associated antigen sequence. Once cells presenting the relevant complex are identified via the foregoing screening methodology, they can be combined with a sample from a patient, where the sample contains CTLs. If the complex presenting cells are lysed by the mixed CTL sample, then it can be assumed that a cancer associated antigen is being
15 presented, and the subject is an appropriate candidate for the therapeutic approaches set forth *supra*.

Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked *in vivo*, using a number of approaches. One approach is the use of non-proliferative cells expressing the complex. The cells used in this
20 approach may be those that normally express the complex, such as irradiated tumor cells or cells transfected with one or both of the genes necessary for presentation of the complex (i.e. the antigenic peptide and the presenting HLA molecule). Chen et al. (*Proc. Natl. Acad. Sci. USA* 88: 110-114,1991) exemplifies this approach, showing the use of transfected cells expressing HPV-E7 peptides in a therapeutic regime. Various cell types may be used.
25 Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred. For example, nucleic acids which encode a cancer associated antigen polypeptide or peptide may be operably linked to promoter and enhancer sequences which direct expression of the cancer associated antigen polypeptide or peptide in certain tissues or cell types. The nucleic acid may be incorporated into an expression vector.
30 Expression vectors may be unmodified extrachromosomal nucleic acids, plasmids or viral genomes constructed or modified to enable insertion of exogenous nucleic acids, such as those encoding cancer associated antigens, as described elsewhere herein. Nucleic acids encoding one or more cancer associated antigens also may be inserted into a retroviral genome, thereby

facilitating integration of the nucleic acid into the genome of the target tissue or cell type. In these systems, the gene of interest is carried by a microorganism, e.g., a Vaccinia virus, pox virus, herpes simplex virus, retrovirus or adenovirus, and the materials de facto "infect" host cells. The cells which result present the complex of interest, and are recognized by 5 autologous CTLs, which then proliferate.

A similar effect can be achieved by combining the cancer associated antigen or a stimulatory fragment thereof with an adjuvant to facilitate incorporation into antigen presenting cells *in vivo*. The cancer associated antigen polypeptide is processed to yield the peptide partner of the HLA molecule while a cancer associated antigen peptide may be 10 presented without the need for further processing. Generally, subjects can receive an intradermal injection of an effective amount of the cancer associated antigen. Initial doses can be followed by booster doses, following immunization protocols standard in the art. Preferred cancer associated antigens include those found to react with allogeneic cancer antisera, shown in the examples below.

15 The invention involves the use of various materials disclosed herein to "immunize" subjects or as "vaccines". As used herein, "immunization" or "vaccination" means increasing or activating an immune response against an antigen. It does not require elimination or eradication of a condition but rather contemplates the clinically favorable enhancement of an immune response toward an antigen. Generally accepted animal models can be used for 20 testing of immunization against cancer using a cancer associated antigen nucleic acid. For example, human cancer cells can be introduced into a mouse to create a tumor, and one or more cancer associated antigen nucleic acids can be delivered by the methods described herein. The effect on the cancer cells (e.g., reduction of tumor size) can be assessed as a measure of the effectiveness of the cancer associated antigen nucleic acid immunization. Of 25 course, testing of the foregoing animal model using more conventional methods for immunization can include the administration of one or more cancer associated antigen polypeptides or peptides derived therefrom, optionally combined with one or more adjuvants and/or cytokines to boost the immune response. Methods for immunization, including formulation of a vaccine composition and selection of doses, route of administration and the 30 schedule of administration (e.g. primary and one or more booster doses), are well known in the art. The tests also can be performed in humans, where the end point is to test for the presence of enhanced levels of circulating CTLs against cells bearing the antigen, to test for levels of circulating antibodies against the antigen, to test for the presence of cells expressing

the antigen and so forth.

As part of the immunization compositions, one or more cancer associated antigens or stimulatory fragments thereof are administered with one or more adjuvants to induce an immune response or to increase an immune response. An adjuvant is a substance incorporated into or administered with antigen which potentiates the immune response. Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes. Adjuvants of many kinds are well known in the art. Specific examples of adjuvants include monophosphoryl lipid A (MPL, SmithKline Beecham), a congener obtained after purification and acid hydrolysis of *Salmonella minnesota* Re 595 lipopolysaccharide; saponins including QS21 (SmithKline Beecham), a pure QA-21 saponin purified from *Quillja saponaria* extract; DQS21, described in PCT application WO96/33739 (SmithKline Beecham); QS-7, QS-17, QS-18, and QS-L1 (So et al., *Mol. Cells* 7:178-186, 1997); incomplete Freund's adjuvant; complete Freund's adjuvant; montanide; alum; CpG oligonucleotides (see e.g. Kreig et al., *Nature* 374:546-9, 1995); and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol. Preferably, the peptides are administered mixed with a combination of DQS21/MPL. The ratio of DQS21 to MPL typically will be about 1:10 to 10:1, preferably about 1:5 to 5:1 and more preferably about 1:1. Typically for human administration, DQS21 and MPL will be present in a vaccine formulation in the range of about 1 μg to about 100 μg. Other adjuvants are known in the art and can be used in the invention (*see, e.g.* Goding, *Monoclonal Antibodies: Principles and Practice*, 2nd Ed., 1986). Methods for the preparation of mixtures or emulsions of peptide and adjuvant are well known to those of skill in the art of vaccination.

Other agents which stimulate the immune response of the subject can also be administered to the subject. For example, other cytokines are also useful in vaccination protocols as a result of their lymphocyte regulatory properties. Many other cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-12 (IL-12) which has been shown to enhance the protective effects of vaccines (*see, e.g., Science* 268: 1432-1434, 1995), GM-CSF and IL-18. Thus cytokines can be administered in conjunction with antigens and adjuvants to increase the immune response to the antigens.

There are a number of immune response potentiating compounds that can be used in vaccination protocols. These include costimulatory molecules provided in either protein or nucleic acid form. Such costimulatory molecules include the B7-1 and B7-2 (CD80 and CD86

respectively) molecules which are expressed on dendritic cells (DC) and interact with the CD28 molecule expressed on the T cell. This interaction provides costimulation (signal 2) to an antigen/MHC/TCR stimulated (signal 1) T cell, increasing T cell proliferation and effector function. B7 also interacts with CTLA4 (CD152) on T cells and studies involving CTLA4 5 and B7 ligands indicate that the B7-CTLA4 interaction can enhance antitumor immunity and CTL proliferation (Zheng P., et al. *Proc. Natl. Acad. Sci. USA* 95 (11):6284-6289 (1998)).

B7 typically is not expressed on tumor cells so they are not efficient antigen presenting cells (APCs) for T cells. Induction of B7 expression would enable the tumor cells to stimulate more efficiently CTL proliferation and effector function. A combination of B7/IL-6/IL-12 10 costimulation has been shown to induce IFN-gamma and a Th1 cytokine profile in the T cell population leading to further enhanced T cell activity (Gajewski et al., *J. Immunol*, 154:5637-5648 (1995)). Tumor cell transfection with B7 has ben discussed in relation to *in vitro* CTL expansion for adoptive transfer immunotherapy by Wang et al., (*J. Immunol.*, 19:1-8 (1986)). Other delivery mechanisms for the B7 molecule would include nucleic acid (naked DNA) 15 immunization (Kim J., et al. *Nat Biotechnol.*, 15:7:641-646 (1997)) and recombinant viruses such as adeno and pox (Wendtner et al., *Gene Ther.*, 4:7:726-735 (1997)). These systems are all amenable to the construction and use of expression cassettes for the coexpression of B7 with other molecules of choice such as the antigens or fragment(s) of antigens discussed herein (including polytopes) or cytokines. These delivery systems can be used for induction 20 of the appropriate molecules *in vitro* and for *in vivo* vaccination situations. The use of anti-CD28 antibodies to directly stimulate T cells *in vitro* and *in vivo* could also be considered. Similarly, the inducible co-stimulatory molecule ICOS which induces T cell responses to foreign antigen could be modulated, for example, by use of anti-ICOS antibodies (Hutloff et al., *Nature* 397:263-266, 1999).

25 Lymphocyte function associated antigen-3 (LFA-3) is expressed on APCs and some tumor cells and interacts with CD2 expressed on T cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Parra et al., *J. Immunol.*, 158:637-642 (1997), Fenton et al., *J. Immunother.*, 21:2:95-108 (1998)).

30 Lymphocyte function associated antigen-1 (LFA-1) is expressed on leukocytes and interacts with ICAM-1 expressed on APCs and some tumor cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Fenton et al., *J. Immunother.*, 21:2:95-108 (1998)).

LFA-1 is thus a further example of a costimulatory molecule that could be provided in a vaccination protocol in the various ways discussed above for B7.

Complete CTL activation and effector function requires Th cell help through the interaction between the Th cell CD40L (CD40 ligand) molecule and the CD40 molecule expressed by DCs (Ridge et al., *Nature*, 393:474 (1998), Bennett et al., *Nature*, 393:478 (1998), Schoenberger et al., *Nature*, 393:480 (1998)). This mechanism of this costimulatory signal is likely to involve upregulation of B7 and associated IL-6/IL-12 production by the DC (APC). The CD40-CD40L interaction thus complements the signal 1 (antigen/MHC-TCR) and signal 2 (B7-CD28) interactions.

The use of anti-CD40 antibodies to stimulate DC cells directly, would be expected to enhance a response to tumor antigens which are normally encountered outside of a inflammatory context or are presented by non-professional APCs (tumor cells). In these situations Th help and B7 costimulation signals are not provided. This mechanism might be used in the context of antigen pulsed DC based therapies or in situations where Th epitopes have not been defined within known TRA precursors.

A cancer associated antigen polypeptide, or a fragment thereof, also can be used to isolate their native binding partners. Isolation of such binding partners may be performed according to well-known methods. For example, isolated cancer associated antigen polypeptides can be attached to a substrate (e.g., chromatographic media, such as polystyrene beads, or a filter), and then a solution suspected of containing the binding partner may be applied to the substrate. If a binding partner which can interact with cancer associated antigen polypeptides is present in the solution, then it will bind to the substrate-bound cancer associated antigen polypeptide. The binding partner then may be isolated.

It will also be recognized that the invention embraces the use of the cancer associated antigen cDNA sequences in expression vectors, as well as to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., dendritic cells, B cells, CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as human, mouse, hamster, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include keratinocytes, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

The invention also contemplates delivery of nucleic acids, polypeptides or peptides for

vaccination. Delivery of polypeptides and peptides can be accomplished according to standard vaccination protocols which are well known in the art. In another embodiment, the delivery of nucleic acid is accomplished by *ex vivo* methods, i.e. by removing a cell from a subject, genetically engineering the cell to include a cancer associated antigen, and reintroducing the engineered cell into the subject. One example of such a procedure is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction *in vitro* of a functional copy of a gene into a cell(s) of a subject, and returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654. *In vivo* nucleic acid delivery using vectors such as viruses and targeted liposomes also is contemplated according to the invention.

In preferred embodiments, a virus vector for delivering a nucleic acid encoding a cancer associated antigen is selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses including vaccinia viruses and attenuated poxviruses, Semliki Forest virus, Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, and Ty virus-like particle. Examples of viruses and virus-like particles which have been used to deliver exogenous nucleic acids include: replication-defective adenoviruses (e.g., Xiang et al., *Virology* 219:220-227, 1996; Eloit et al., *J. Virol.* 7:5375-5381, 1997; Chengalvala et al., *Vaccine* 15:335-339, 1997), a modified retrovirus (Townsend et al., *J. Virol.* 71:3365-3374, 1997), a nonreplicating retrovirus (Irwin et al., *J. Virol.* 68:5036-5044, 1994), a replication defective Semliki Forest virus (Zhao et al., *Proc. Natl. Acad. Sci. USA* 92:3009-3013, 1995), canarypox virus and highly attenuated vaccinia virus derivative (Paoletti, *Proc. Natl. Acad. Sci. USA* 93:11349-11353, 1996), non-replicative vaccinia virus (Moss, *Proc. Natl. Acad. Sci. USA* 93:11341-11348, 1996), replicative vaccinia virus (Moss, *Dev. Biol. Stand.* 82:55-63, 1994), Venzuelan equine encephalitis virus (Davis et al., *J. Virol.* 70:3781-3787, 1996), Sindbis virus (Pugachev et al., *Virology* 212:587-594, 1995), and Ty virus-like particle (Allsopp et al., *Eur. J. Immunol* 26:1951-1959, 1996). In preferred embodiments, the virus vector is an adenovirus.

Another preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus is capable of infecting a wide range

of cell types and species and can be engineered to be replication-deficient. It further has advantages, such as heat and lipid solvent stability, high transduction frequencies in cells of diverse lineages, including hematopoietic cells, and lack of superinfection inhibition thus allowing multiple series of transductions. The adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

In general, other preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Adenoviruses and retroviruses have been approved for human gene therapy trials. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., "Gene Transfer and Expression, A Laboratory Manual," W.H. Freeman Co., New York (1990) and Murry, E.J. Ed. "Methods in Molecular Biology," vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Preferably the foregoing nucleic acid delivery vectors: (1) contain exogenous genetic material that can be transcribed and translated in a mammalian cell and that can induce an immune response in a host, and (2) contain on a surface a ligand that selectively binds to a receptor on the surface of a target cell, such as a mammalian cell, and thereby gains entry to the target cell.

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid-$CaPO_4$ precipitates, transfection of

nucleic acids associated with DEAE, transfection or infection with the foregoing viruses including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle. Preferred antibodies include antibodies which selectively bind a cancer associated antigen, alone or as a complex with a MHC molecule. Especially preferred are monoclonal antibodies. Where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral delivery of nucleic acids.

The therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal. When cancer associated antigen peptides are used for vaccination, modes of administration which effectively deliver the cancer associated antigen and adjuvant, such that an immune response to the antigen is increased, can be used. For administration of a cancer associated antigen peptide in adjuvant, preferred methods include intradermal, intravenous, intramuscular and subcutaneous administration. Although these are preferred embodiments, the invention is not limited by the particular modes of administration disclosed herein. Standard references in the art (e.g., *Remington's Pharmaceutical Sciences*, 18th edition, 1990) provide modes of administration and formulations for delivery of immunogens with adjuvant or in a non-adjuvant carrier. When antibodies are used therapeutically, a preferred route of administration is by pulmonary aerosol. Techniques for preparing aerosol delivery systems containing antibodies are well known to those of skill in the art. Generally, such systems should utilize components which will not significantly impair the biological properties of the antibodies, such as the paratope binding capacity (see, for example, Sciarra and Cutie,

"Aerosols," in Remington's Pharmaceutical Sciences, 18th edition, 1990, pp 1694-1712; incorporated by reference). Those of skill in the art can readily determine the various parameters and conditions for producing antibody aerosols without resort to undue experimentation. When using antisense preparations of the invention, slow intravenous administration is preferred.

The compositions of the invention are administered in effective amounts. An "effective amount" is that amount of a cancer associated antigen composition that alone, or together with further doses, produces the desired response, e.g. increases an immune response to the cancer associated antigen. In the case of treating a particular disease or condition characterized by expression of one or more cancer associated antigens, such as breast cancer or T cell leukemia, the desired response is inhibiting the progression of the disease. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods or can be monitored according to diagnostic methods of the invention discussed herein. The desired response to treatment of the disease or condition also can be delaying the onset or even preventing the onset of the disease or condition.

Such amounts will depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

The pharmaceutical compositions used in the foregoing methods preferably are sterile and contain an effective amount of cancer associated antigen or nucleic acid encoding cancer associated antigen for producing the desired response in a unit of weight or volume suitable for administration to a patient. The response can, for example, be measured by determining the immune response following administration of the cancer associated antigen composition via a reporter system by measuring downstream effects such as gene expression, or by measuring the physiological effects of the cancer associated antigen composition, such as

regression of a tumor or decrease of disease symptoms. Other assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the response.

The doses of cancer associated antigen compositions (e.g., polypeptide, peptide, antibody, cell or nucleic acid) administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject. Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits.

In general, for treatments for eliciting or increasing an immune response, doses of cancer associated antigen are formulated and administered in doses between 1 ng and 1 mg, and preferably between 10 ng and 100 μg, according to any standard procedure in the art. Where nucleic acids encoding cancer associated antigen of variants thereof are employed, doses of between 1 ng and 0.1 mg generally will be formulated and administered according to standard procedures. Other protocols for the administration of cancer associated antigen compositions will be known to one of ordinary skill in the art, in which the dose amount, schedule of injections, sites of injections, mode of administration (e.g., intra-tumoral) and the like vary from the foregoing. Administration of cancer associated antigen compositions to mammals other than humans, e.g. for testing purposes or veterinary therapeutic purposes, is carried out under substantially the same conditions as described above.

When administered, the pharmaceutical compositions of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable preparations. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like. Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

A cancer associated antigen composition may be combined, if desired, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.

The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.

The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of cancer associated antigen polypeptides or nucleic acids, which is preferably isotonic with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or di-glycerides. In

addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for oral, subcutaneous, intravenous, intramuscular, etc. administrations can be found in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA.

5

Examples

Example 1: SEREX screening of breast cancer cells

The procedures of cDNA library preparation and screening were standard. The breast cancer library was made from mRNA isolated from a breast tumor of a 59-year old female patient in a ZAP Express vector using a cDNA library kit (Stratagene, La Jolla, CA). The T
10 cell leukemia library was made from mRNA isolated from adult T cell leukemia cells. The cDNA libraries were screened with autologous patient's serum as described by Sahin et al., *Proc. Natl. Acad. Sci. USA* 92:11810-11813, 1995.

The following modifications were made to the standard procedure. An *E. coli* lysate and *E. coli* phage lysate coupled to Sepharose 4B (5 Prime-3 Prime, Boulder CO, Cat
15 #5307-050901 and #5307-110901) were used to preabsorb the serum. The preabsorbed serum was diluted 1:200 and incubated overnight at +4°C with the nitrocellulose membranes containing the phage plaques. Clones encoding human immunoglobulin sequences were revealed after incubation with peroxidase conjugated goat anti-human IgG, Fc-gamma fragment specific (Jackson Immunoresearch Labs.Inc. Cat.#109-035-008) and visualization by
20 3,3'-diaminobenzidine. After washing, the membranes were incubated with alkaline phosphatase conjugated goat anti-human IgG, Fc-gamma fragment specific (Jackson Immunoresearch Labs.Inc. Cat.#109-055-008), and reactive phage plaques were visualized by incubation with 5-bromo-4-chloro-3-indolyl-phosphate and nitroblue tetrazolium.

Clones were purified and the nucleic acid sequences were analyzed. Comparisons of
25 the sequences showed that these clones represented cDNAs from two distinct genes.

The first gene includes four nucleotide sequences presented herein. Clone HOM-TALL1-5 was isolated from the adult T-cell leukemia library. HOM-TALL1-5 sequences include HOM-TALL1-5 (5') (SEQ ID NO:1) and HOM-TALL1-5 (3') (SEQ ID NO:3). Clone MO-BC-203 was isolated from the breast cancer library. MO-BC-203
30 sequences include MO-BC-203 (5') (SEQ ID NO:4) and MO-BC-203 (3') (SEQ ID NO:6). The polypeptides encoded by the long open reading frames of these sequences include the amino acids set forth as SEQ ID NO:2 (HOM-TALL1-5) and SEQ ID NO:5 (MO-BC-203). The T-cell and breast clones are not identical, and thus may represent allelic variants of the

same gene from different individuals. Overlaps in the clones are as follows: nucleotides 469-1178 of HOM-TALL1-5 (5') (SEQ ID NO:1) match nucleotides 1-712 of MO-BC-203 (5') (SEQ ID NO:4); nucleotides 1-524 of HOM-TALL1-5 (3') (SEQ ID NO:3) match nucleotides 44-567 of MO-BC-203 (3') (SEQ ID NO:6).

5 Clones MO-BC-203 and HOM-TALL1-5 represent 80-90% of an unknown gene, and are homologous in part to human tankyrase, a TRF1-interacting ankyrin-related ADP-ribose polymerase. The full length RNA based in tissue blot analysis is about 7 kb. It is expressed in skeletal muscles and placenta, and to lesser extent in other tissues.

Sequences similar to HOM-TALL1-5 and MO-BC-203 in the National Cancer
10 Institute Cancer Genome Anatomy Project (NCI CGAP) database are from kidney cancer, adrenal adenoma, colon adenocarcinoma, pancreatic carcinoma, and uterus adenocarcinoma, some of which are listed in Table 4.

The protein encoded by clone MO-BC-203 positively reacts with 4 out of 11 breast cancer sera tested.

15 The second gene, MO-BC-416 (SEQ ID NO:7), was isolated from the breast cancer library. The polypeptide of the long open reading frame encoded by MO-BC-416 nucleotide sequence is set forth as (SEQ ID NO:8).

Clone MO-BC-416 represents an novel alternative transcript of a known gene, Cxorf5, which does not contain exon 19 of Cxorf5. Two alternative transcripts of Cxorf5 had been
20 described previously (deConciliis et al., *Genomics* 51(2):243-250 (1998)). The previously described alternative transcripts differ in containing an exon 10 (transcript Cxorf5-1, emb|Y15164|HS717AX) or an exon 10a (transcript Cxorf5-2, emb|Y16355|HS717AXAS). Exon 10 of clone MO-BC-416 is organized similarly to transcript Cxorf5-1 (emb|Y15164|HS717AX). In addition to the lack of exon 19, clone MO-BC-416 is truncated
25 at its 5' end by 1042 bp relative to Cxorf5-1, and its 3' end is shorter than that in Cxorf5-1 because of an alternative polyadenylation signal.

The two previously known transcripts of the gene Cxorf5 have different distribution in human tissues. For example, the Cxorf5-1 transcript is ubiquitously expressed, while the Cxorf5-2 transcript is not expressed in skeletal muscles, liver, and heart.

30 Sequences similar to MO-BC-416 in the National Cancer Institute Cancer Genome Anatomy Project (NCI CGAP) database are from germ cell tumor, colon adenocarcinoma, ovarian cancer, Wilms tumor and breast tumor, some of which are listed in Table 4.

The protein encoded by clone MO-BC-416 does not react with 24 normal sera, but it

does react with 1 out of 11 breast cancer sera, and also 1 out of 3 renal cancer sera (not Wilms tumor). Renal cell carcinoma and Wilms tumor (nephroblastoma) are not the same. Wilms tumor is fairly rare form of renal cancer occuring predominantly in children <4 yrs old and involves a chromosome 11 mutation.

Example 2: Preparation of recombinant cancer associated antigens

To facilitate screening of patients' sera for antibodies reactive with cancer associated antigens, for example by ELISA, recombinant proteins are prepared according to standard procedures. In one method, the clones encoding cancer associated antigens are subcloned into a baculovirus expression vector, and the recombinant expression vectors are introduced into appropriate insect cells. Baculovirus/insect cloning systems are preferred because post-translational modifications are carried out in the insect cells. Another preferred eukaryotic system is the *Drosophila* Expression System from Invitrogen. Clones which express high amounts of the recombinant protein are selected and used to produce the recombinant proteins. The recombinant proteins are tested for antibody recognition using serum from the patient which was used to isolated the particular clone, or in the case of cancer associated antigens recognized by allogeneic sera, by the sera from any of the patients used to isolate the clones or sera which recognize the clones' gene products.

Alternatively, the cancer associated antigen clones are inserted into a prokaryotic expression vector for production of recombinant proteins in bacteria. Other systems, including yeast expression systems and mammalian cell culture systems also can be used.

Example 3: Preparation of antibodies to cancer associated antigens

The recombinant cancer associated antigens produced as in Example 2 above are used to generate polyclonal antisera and monoclonal antibodies according to standard procedures. The antisera and antibodies so produced are tested for correct recognition of the cancer associated antigens by using the antisera/antibodies in assays of cell extracts of patients known to express the particular cancer associated antigen (e.g. an ELISA assay). These antibodies can be used for experimental purposes (e.g. localization of the cancer associated antigens, immunoprecipitations, Western blots, etc.) as well as diagnostic purposes (e.g., testing extracts of tissue biopsies, testing for the presence of cancer associated antigens).

Example 4: Expression of breast cancer and T cell leukemia associated antigens in cancers of

similar and different origin.

The expression of one or more of the breast cancer and T cell leukemia associated antigens is tested in a range of tumor samples to determine which, if any, other malignancies should be diagnosed and/or treated by the methods described herein. Tumor cell lines and tumor samples are tested for cancer associated antigen expression, preferably by RT-PCR according to standard procedures. Northern blots also are used to test the expression of the cancer associated antigens. Antibody based assays, such as ELISA and western blot, also can be used to determine protein expression. A preferred method of testing expression of cancer associated antigens (in other cancers and in additional same type cancer patients) is allogeneic serotyping using a modified SEREX protocol (as described above).

In all of the foregoing, extracts from the tumors of patients who provided sera for the initial isolation of the cancer associated antigens are used as positive controls. The cells containing recombinant expression vectors described in the Examples above also can be used as positive controls.

The results generated from the foregoing experiments provide panels of multiple cancer associated nucleic acids and/or polypeptides for use in diagnostic (e.g. determining the existence of cancer, determining the prognosis of a patient undergoing therapy, etc.) and therapeutic methods (e.g., vaccine composition, etc.).

Example 5: HLA typing of patients positive for cancer associated antigen

To determine which HLA molecules present peptides derived from the cancer associated antigens, cells of the patients which express the breast cancer and/or T cell leukemia associated antigens are HLA typed. Peripheral blood lymphocytes are taken from the patient and typed for HLA class I or class II, as well as for the particular subtype of class I or class II. Tumor biopsy samples also can be used for typing. HLA typing can be carried out by any of the standard methods in the art of clinical immunology, such as by recognition by specific monoclonal antibodies, or by HLA allele-specific PCR (e.g. as described in WO97/31126).

Example 6: Characterization of cancer associated antigen peptides presented by MHC class I and class II molecules.

Antigens which provoke an antibody response in a subject may also provoke a cell-mediated immune response. Cells process proteins into peptides for presentation on MHC

class I or class II molecules on the cell surface for immune surveillance. Peptides presented by certain MHC/HLA molecules generally conform to motifs. These motifs are known in some cases, and can be used to screen the breast cancer and/or T cell leukemia associated antigens for the presence of potential class I and/or class II peptides. Summaries of class I and class II motifs have been published (e.g., Rammensee et al., *Immunogenetics* 41:178-228, 1995). Based on the results of experiments such as those described above, the HLA types which present the individual breast cancer and/or T cell leukemia associated antigens are known. Motifs of peptides presented by these HLA molecules thus are preferentially searched.

One also can search for class I and class II motifs using computer algorithms. For example, computer programs for predicting potential CTL epitopes based on known class I motifs has been described (*see, e.g.,* Parker et al, *J. Immunol.* 152:163, 1994; D'Amaro et al., *Human Immunol.* 43:13-18, 1995; Drijfhout et al., *Human Immunol.* 43:1-12, 1995). HLA binding predictions can conveniently be made using an algorithm available via the Internet on the National Institutes of Health World Wide Web site at URL http://bimas.dcrt.nih.gov. Methods for determining HLA class II peptides and making substitutions thereto are also known (e.g. Strominger and Wucherpfennig (PCT/US96/03182)).

Example 7: Identification of the portion of a cancer associated polypeptide encoding an antigen

To determine if the cancer associated antigens isolated as described above can provoke a cytolytic T lymphocyte response, the following method is performed. CTL clones are generated by stimulating the peripheral blood lymphocytes (PBLs) of a patient with autologous normal cells transfected with one of the clones encoding a cancer associated antigen polypeptide or with irradiated PBLs loaded with synthetic peptides corresponding to the putative protein and matching the consensus for the appropriate HLA class I molecule (as described above) to localize an antigenic peptide within the cancer associated antigen clone (*see*, e.g., Knuth et al., *Proc. Natl. Acad. Sci. USA* 81:3511-3515, 1984; van der Bruggen et al., *Eur. J. Immunol.*24:3038-3043, 1994). These CTL clones are screened for specificity against COS cells transfected with the cancer associated antigen clone and autologous HLA alleles as described by Brichard et al. (*Eur. J. Immunol.* 26:224-230, 1996). CTL recognition of a cancer associated antigen is determined by measuring release of TNF from the cytolytic T lymphocyte or by ^{51}Cr release assay (Herin et al., *Int. J. Cancer* 39:390-396, 1987). If a CTL

clone specifically recognizes a transfected COS cell, then shorter fragments of the cancer associated antigen clone transfected in that COS cell are tested to identify the region of the gene that encodes the peptide. Fragments of the cancer associated antigen clone are prepared by exonuclease III digestion or other standard molecular biology methods. Synthetic peptides are prepared to confirm the exact sequence of the antigen.

Optionally, shorter fragments of cancer associated antigen cDNAs are generated by PCR. Shorter fragments are used to provoke TNF release or ^{51}Cr release as above.

Synthetic peptides corresponding to portions of the shortest fragment of the cancer associated antigen clone which provokes TNF release are prepared. Progressively shorter peptides are synthesized to determine the optimal cancer associated antigen tumor rejection antigen peptides for a given HLA molecule.

A similar method is performed to determine if the cancer associated antigen contains one or more HLA class II peptides recognized by T cells. One can search the sequence of the cancer associated antigen polypeptides for HLA class II motifs as described above. In contrast to class I peptides, class II peptides are presented by a limited number of cell types. Thus for these experiments, dendritic cells or B cell clones which express HLA class II molecules preferably are used.

Example 8: Determination of full-length MO-BC-203 nucleic acid molecule

The MO-BC-203 clones identified in Example 1 were extended by standard procedures to obtain the full length nucleotide and amino acid sequences of this gene product. The nucleotide sequence is presented as SEQ ID NO:9, and the amino acid sequence is presented as SEQ ID NO:10.

Example 9: Expression of MO-BC-203 antigen in cancer patient sera

The MO-BC-203 antigen was tested for reactivity with sera from the normal and various cancer patients listed below.

Table 1: Serology of MO-BC-203 antigen

Sera	Reactivity
Breast cancer	26/105
Renal cancer	5/60
Colon cancer	6/30

Head & neck cancer	4/30
Ovarian cancer	0/23
Melanoma	0/11
Normal	4/115

Example 10: Determination of peptide epitopes of MO-BC-203

To identify possible epitopes of MO-BC-203, overlapping peptides derived from MO-BC-203 protein were synthesized and tested for recognition by $CD8^+$ T lymphocytes in autologous settings. $CD8^+$ T lymphocyte responses were determined using a commercially available enzyme-linked immunospot (ELISPOT) assay system for IFN-γ according to the manufacturer's instructions. Five MO-BC-203 derived peptides were identified as recognized by CD8+ T lymphocytes of an HLA-A2 positive breast cancer patient (NW1100): DLADPSAKAV (SEQ ID NO:11), LLSYGADPTL (SEQ ID NO:12), LLAHGADPTL (SEQ ID NO:13), GMFGAGIYFA (SEQ ID NO:14), ATADALFQV (SEQ ID NO:15).

The specificity of recognition of these five peptides was confirmed by proliferation assays. $HLA\text{-}A2^+$ T2 target cells were labeled with ^{51}Cr, as described above and then were incubated in 96-well microplates in the presence the MO-BC-203 peptides for 30 minutes. CTLs from an HLA-A2 positive breast cancer patient (NW1100) which recognize the peptide presented by the HLA were then added in an equal volume of medium at a various effector:target ratios (see Table 2). Chromium-51 release was measured after 4 hours. The percentage of specific lysis was calculated as follows:

$$\% \text{ specific lysis} = \frac{\text{experimental release - spontaneous release}}{\text{total release - spontaneous release}} \times 100$$

The peptide GMFGAGIYFA (SEQ ID NO:14) was positive in these cytotoxicity assays, as shown below in Table 2.

Table 2: Lysis of MO-BC-203 peptide (SEQ ID NO:) pulsed T2 cells

Effector: Target Ratio	T2 + Peptide(%)	T2 (%)
90:1	75	1
30:1	60	0
10:1	37	0
1:1	14	0

Example 11: SEREX screening of ovarian cancer cells

A cDNA library was made from mRNA isolated from ovarian cancer cells. The cDNA library was screened with autologous patient's serum as described above and by Sahin et al., *Proc. Natl. Acad. Sci. USA* 92:11810-11813, 1995. The isolated sequence, MOVA-91 (nucleotide sequence: SEQ ID NO:16; polypeptide sequence: SEQ ID NO:17), appears to be derived from the *Homo sapiens* histone deacetylase 3 gene (HDAC3, Yang et al., *J. Biol. Chem.* 272(44):28001-28007, 1997; Genbank accession numbers NM_003883.1, U66914, AF039703, U75697, U75696, AF005482).

The known transcript of the HDAC3 gene is ubiquitously expressed in many cell types (Yang et al., 1997), with somewhat less expression in brain tissue, and unchanged expression in tumor cell lines.

Sequences similar to MOVA-91 in the GenBank database (National Cancer Institute Cancer Genome Anatomy Project (NCI CGAP) and other sources) are from squamous cell carcinoma, glioblastoma (pooled), anaplastic oligodendroglioma, B-cell chronic lymphotic leukemia, larynx, uterus and germinal center B cell tumors. Other sequences with limited identity were found in a colon carcinoma (HCC) cell line and a T84 carcinoma cell line. Some of the foregoing are listed in Table 4.

The protein encoded by clone MOVA-91 positively reacted with cancer sera in a serology test as shown in Table 3.

Table 3: Serology of MOVA-91 antigen

Sera	Reactivity
Ovarian cancer	3/29
Breast cancer	4/22
Colon cancer	5/40
Normal	0/30

Table 4: Sequence homologies: GenBank Accession Numbers

HOM-TALL1-5 5' (SEQ ID NO:1)
AF082556, AF082557, R64714, N66032, AA977611, AI120891, AI462502, AA088990,

AA675357.

HOM-TALL1-5 3' (SEQ ID NO:3)
AA203305, AA305897, C01749, H80193, AA247547, AI431629, H10461, AA864829,
5 AA265558, AA462373, AI540752, AI457343.

MO-BC-203 5' (SEQ ID NO:4)
AF082556, AF082557, R64714, N66032, AA977611, AI120891, AI462502, AA088990,
AA675357.
10

MO-BC-203 3' (SEQ ID NO:6)
AI431629, N67275, C01749, AA864829, R58932, H10462, AA531283, AA565321, T07723,
R61199, AA305897, AI540752, AI457343.

15 MO-BC-416 (SEQ ID NO:7)
Y15164, Y16355, AI634116, AI627406, AI245948, AI309530, AI304731, AI280957,
AA514458, AA994778, AI471729, AI561264.

MO-BC-203 (SEQ ID NO:9)

20 NM_003747.1, AF082557.1, AF082556.1, AL078591.18, AC012147.7, NM_003344.1,
AF082559.1, AL163243.2, AP001698.1, AP001603.1, Z29331.1, Z29330.1, R64714.1,
AI808818.1, AW173142.1, AI674096.1, AI935063.1, AI674111.1, AI418384.1,
AA307492.1, AA203305.1, AW749617.1, AW238878.1, AI287632.1, AW206871.1,
AI381961.1, AI890286.1, N29528.1, AI431629.1, AA305587.1, AA305897.1, AI913516.1,
25 AA244138.1, AA244137.1, R62976.1, H10461.1, AI040839.1, C01749.1, T17118.1,
H11865.1, H17748.1, AI247608.1, H80193.1, AW511978.1, AA970617.1, R61198.1,
AA774553.1, R63338.1, AA329699.1, R63031.1, AI819460.1, AW231078.1, AW243789.1,
AW026572.1, AW027833.1, AA371079.1, N67275.1, H11505.1, R14158.1, AW139568.1,
AA329948.1, N57467.1, AA247547.1, AA864829.1, R63337.1, R33944.1, AA337757.1,
30 R58932.1, H17635.1, H10462.1, AI802966.1, AI643100.1, R06902.1, AA088990.1,
AA531283.1, AA565321.1, AW486778.1, T07723.1, AW073280.1, AA409177.1, T55659.1,
AW157349.1, AA039614.1, AI565257.1, R06946.1, N46626.1, R61199.1, R19912.1,
AI462502.1, AI120891.1, T25153.1, AA318909.1, AW681989.1, AI262121.1, AI444969.1,
AI872648.1, AI426537.1, AA963756.1, C78555.1, T55578.1, R40453.1, AA517131.1,
35 N40466.1, AI003014.1, N34900.1, H78817.1, AW446342.1, N66032.1, AA119881.1,
AW545039.1, AW539288.1, AI457343.1, AL161648.5, AL354864.1, AC024971.1,
AC016932.3, AC023880.2, AC021968.3, AC015797.2.

MOVA-91 (SEQ ID NO:16)

40 NM_003883.1, U66914, AF039703, U75697, U75696, AF005482, AI831781, AA648417,
AI362269, AI553758, AI393982, AA584221, AA298993, AA313537, AA045846.

EQUIVALENTS

45 Those skilled in the art will recognize, or be able to ascertain using no more than

routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

All references disclosed herein are incorporated by reference in their entirety.

5 We claim:

Claims

1. A method of diagnosing a disorder characterized by expression of a human cancer associated antigen precursor coded for by a nucleic acid molecule, comprising:

contacting a biological sample isolated from a subject with an agent that specifically binds to the nucleic acid molecule, an expression product thereof, or a fragment of an expression product thereof complexed with an HLA molecule, wherein the nucleic acid molecule is a NA Group 1 nucleic acid molecule, and

determining the interaction between the agent and the nucleic acid molecule or the expression product as a determination of the disorder.

2. The method of claim 1, wherein the agent is selected from the group consisting of

(a) a nucleic acid molecule comprising NA group 1 nucleic acid molecules or a fragment thereof,

(b) a nucleic acid molecule comprising NA group 3 nucleic acid molecules or a fragment thereof,

(c) a nucleic acid molecule comprising NA group 5 nucleic acid molecules or a fragment thereof,

(d) an antibody that binds to an expression product of NA group 1 nucleic acids,

(e) an antibody that binds to an expression product of NA group 3 nucleic acids,

(f) an antibody that binds to an expression product of NA group 5 nucleic acids,

(g) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a NA group 1 nucleic acid,

(h) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a NA group 3 nucleic acid, and

(i) an agent that binds to a complex of an HLA molecule and a fragment of an expression product of a NA group 5 nucleic acid.

3. The method of claim 1, wherein the disorder is characterized by expression of a plurality of human cancer associated antigen precursors and wherein the agent is a plurality of agents, each of which is specific for a different human cancer associated antigen precursor, and wherein said plurality of agents is at least 2, at least 3, at least 4, at least 4, at least 6, at least 7, or at least 8, at least 9 or at least 10 such agents.

4. The method of claims 1-3, wherein the agent is specific for a human cancer associated antigen precursor that is a breast cancer, T cell leukemia and/or ovarian cancer associated antigen precursor.

5 5. A method for determining regression, progression or onset of a condition characterized by expression of abnormal levels of a protein encoded by a nucleic acid molecule that is a NA Group 1 molecule, comprising

monitoring a sample, from a patient who has or is suspected of having the condition, for a parameter selected from the group consisting of

10 (i) the protein,

(ii) a peptide derived from the protein,

(iii) an antibody which selectively binds the protein or peptide, and

(iv) cytolytic T cells specific for a complex of the peptide derived from the protein and an MHC molecule,

15 as a determination of regression, progression or onset of said condition.

6. The method of claim 5, wherein the sample is a body fluid, a body effusion or a tissue.

7. The method of claim 5, wherein the step of monitoring comprises contacting the
20 sample with a detectable agent selected from the group consisting of

(a) an antibody which selectively binds the protein of (i), or the peptide of (ii),

(b) a protein or peptide which binds the antibody of (iii), and

(c) a cell which presents the complex of the peptide and MHC molecule of (iv).

25 8. The method of claim 7, wherein the antibody, the protein, the peptide or the cell is labeled with a radioactive label or an enzyme.

9. The method of claim 5, comprising assaying the sample for the peptide.

30 10. The method of claim 5, wherein the nucleic acid molecule is a NA Group 3 molecule.

11. The method of claim 5, wherein the nucleic acid molecule is a NA Group 5 molecule.

12. The method of claim 5, wherein the protein is a plurality of proteins, the parameter is a plurality of parameters, each of the plurality of parameters being specific for a different of the plurality of proteins, at least one of which is a cancer associated protein encoded by a NA Group 1 molecule.

5

13. A pharmaceutical preparation for a human subject comprising

an agent which when administered to the subject enriches selectively the presence of complexes of an HLA molecule and a human cancer associated antigen, and

a pharmaceutically acceptable carrier, wherein the human cancer associated antigen is

10 a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule comprises a NA Group 1 molecule.

14. The pharmaceutical preparation of claim 13, wherein the agent comprises a plurality of agents, each of which enriches selectively in the subject complexes of an HLA molecule and a

15 different human cancer associated antigen, wherein at least one of the human cancer associated antigens is encoded by a NA Group 1 molecule.

15. The pharmaceutical preparation of claim 14, wherein the plurality is at least two, at least three, at least four or at least 5 different such agents.

20

16. The pharmaceutical preparation of claim 13, wherein the nucleic acid molecule is a NA Group 3 nucleic acid molecule.

17. The pharmaceutical preparation of claim 13, wherein the agent is selected from the

25 group consisting of

(1) an isolated polypeptide comprising the human cancer associated antigen, or a functional variant thereof,

(2) an isolated nucleic acid operably linked to a promoter for expressing the isolated polypeptide, or functional variant thereof,

30 (3) a host cell expressing the isolated polypeptide, or functional variant thereof, and

(4) isolated complexes of the polypeptide, or functional variant thereof, and an HLA molecule.

18. The pharmaceutical preparation of claims 13-17, further comprising an adjuvant.

19. The pharmaceutical preparation of claim 13, wherein the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant
5 thereof, and wherein the cell is nonproliferative.

20. The pharmaceutical preparation of claim 13, wherein the agent is a cell expressing an isolated polypeptide comprising the human cancer associated antigen or a functional variant thereof, and wherein the cell expresses an HLA molecule that binds the polypeptide.

10

21. The pharmaceutical preparation of claim 13, wherein the agent is at least two, at least three, at least four or at least five different polypeptides, each coding for a different human cancer associated antigen or functional variant thereof, wherein at least one of the human cancer associated antigens is encoded by a NA Group 1 molecule.

15

22. The pharmaceutical preparation of claim 13, wherein the agent is a PP Group 2 polypeptide.

23. The pharmaceutical preparation of claim 13, wherein the agent is a PP Group 3
20 polypeptide or a PP Group 4 polypeptide.

24. The pharmaceutical preparation of claim 20, wherein the cell expresses one or both of the polypeptide and HLA molecule recombinantly.

25 25. The pharmaceutical preparation of claim 20, wherein the cell is nonproliferative.

26. A composition comprising
an isolated agent that binds selectively a PP Group 1 polypeptide.

30 27. The composition of matter of claim 26, wherein the agent binds selectively a PP Group 2 polypeptide.

28. The composition of matter of claim 26, wherein the agent binds selectively a PP

Group 3 polypeptide.

29. The composition of matter of claim 26, wherein the agent binds selectively a PP Group 4 polypeptide.

5

30. The composition of matter of claim 26, wherein the agent binds selectively a PP Group 5 polypeptide.

31. The composition of claims 26-30, wherein the agent is a plurality of different agents
10 that bind selectively at least two, at least three, at least four, or at least five different such polypeptides.

32. The composition of claims 26-30, wherein the agent is an antibody.

15 33. The composition of claim 31, wherein the agent is an antibody.

34. A composition of matter comprising
a conjugate of the agent of claims 26-30 and a therapeutic or diagnostic agent.

20 35. A composition of matter comprising
a conjugate of the agent of claim 31 and a therapeutic or diagnostic agent.

36. The composition of matter of claim 34, wherein the conjugate is of the agent and a therapeutic or diagnostic that is a toxin.

25

37. A pharmaceutical composition comprising an isolated nucleic acid molecule selected from the group consisting of NA Group 1 molecules and NA Group 2 molecules, and a pharmaceutically acceptable carrier.

30 38. The pharmaceutical composition of claim 37, wherein the isolated nucleic acid molecule comprises a NA Group 3 or NA Group 4 molecule.

39. The pharmaceutical composition of claim 37, wherein the isolated nucleic acid

molecule comprises at least two isolated nucleic acid molecules coding for two different polypeptides, each polypeptide comprising a different human cancer associated antigen.

40. The pharmaceutical composition of claims 37-39 further comprising an expression
5 vector with a promoter operably linked to the isolated nucleic acid molecule.

41. The pharmaceutical composition of claims 37-39 further comprising a host cell recombinantly expressing the isolated nucleic acid molecule.

10 42. A pharmaceutical composition comprising
an isolated polypeptide comprising a PP Group 1 or a PP Group 2 polypeptide, and
a pharmaceutically acceptable carrier.

43. The pharmaceutical composition of claim 42, wherein the isolated polypeptide
15 comprises a PP Group 3 or a PP Group 4 polypeptide.

44. The pharmaceutical composition of claim 42, wherein the isolated polypeptide comprises at least two different polypeptides, each comprising a different human cancer associated antigen.

20

45. The pharmaceutical composition of claim 42, wherein the isolated polypeptides are PP Group 11 polypeptides or HLA binding fragments thereof.

46. The pharmaceutical composition of claim 42, wherein the isolated polypeptides are PP
25 Group 12 polypeptides or HLA binding fragments thereof.

47. The pharmaceutical composition of claims 42-46, further comprising an adjuvant.

48. An isolated nucleic acid molecule comprising a NA Group 3 molecule.

30

49. An isolated nucleic acid molecule comprising a NA Group 4 molecule.

50. An isolated nucleic acid molecule selected from the group consisting of

(a) a fragment of a nucleic acid molecule having a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID Nos:1, 3, 4, 6, 7, 9 and 16, of sufficient length to represent a sequence unique within the human genome, and identifying a nucleic acid encoding a human cancer associated antigen precursor,

5 (b) complements of (a),

provided that the fragment includes a sequence of contiguous nucleotides which is not identical to any sequence selected from the sequence group consisting of

(1) sequences having the GenBank accession numbers of Table 4,

(2) complements of (1), and

10 (3) fragments of (1) and (2).

51. The isolated nucleic acid molecule of claim 50, wherein the sequence of contiguous nucleotides is selected from the group consisting of:

(1) at least two contiguous nucleotides nonidentical to the sequence group,

15 (2) at least three contiguous nucleotides nonidentical to the sequence group,

(3) at least four contiguous nucleotides nonidentical to the sequence group,

(4) at least five contiguous nucleotides nonidentical to the sequence group,

(5) at least six contiguous nucleotides nonidentical to the sequence group,

(6) at least seven contiguous nucleotides nonidentical to the sequence group.

20

52. The isolated nucleic acid molecule of claim 50, wherein the fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides,

25 100 nucleotides, and 200 nucleotides.

53. The isolated nucleic acid molecule of claim 50, wherein the molecule encodes a polypeptide which, or a fragment of which, binds a human HLA receptor or a human antibody.

30

54. An expression vector comprising an isolated nucleic acid molecule of any of claims 48-53 operably linked to a promoter.

55. An expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 2 molecule.

56. An expression vector comprising a NA Group 1 or Group 2 molecule and a nucleic
5 acid encoding an HLA molecule.

57. A host cell transformed or transfected with an expression vector of claim 54.

58. A host cell transformed or transfected with an expression vector of claims 55 or 56.
10

59. A host cell transformed or transfected with an expression vector of claim 54 and further comprising a nucleic acid encoding HLA.

60. A host cell transformed or transfected with an expression vector of claim 55 and
15 further comprising a nucleic acid encoding HLA.

61. An isolated polypeptide encoded by the isolated nucleic acid molecule of claim 48 or claim 49.

20 62. A fragment of the polypeptide of claim 61 which is immunogenic.

63. The fragment of claim 62, wherein the fragment, or a portion of the fragment, binds HLA or a human antibody.

25 64. An isolated fragment of a human cancer associated antigen precursor which, or portion of which, binds HLA or a human antibody, wherein the precursor is encoded by a nucleic acid molecule that is a NA Group 1 molecule.

65. The fragment of claim 64, wherein the fragment is part of a complex with HLA.
30

66. The fragment of claim 65, wherein the fragment is between 8 and 12 amino acids in length.

67. An isolated polypeptide comprising a fragment of the polypeptide of claim 61 of sufficient length to represent a sequence unique within the human genome and identifying a polypeptide that is a human cancer associated antigen precursor.

5 68. A kit for detecting the presence of the expression of a human cancer associated antigen precursor comprising

a pair of isolated nucleic acid molecules each of which consists essentially of a molecule selected from the group consisting of (a) a 12-32 nucleotide contiguous segment of the nucleotide sequence of any of the NA Group 1 molecules and (b) complements of ("a"),
10 wherein the contiguous segments are nonoverlapping.

69. The kit of claim 68, wherein the pair of isolated nucleic acid molecules is constructed and arranged to selectively amplify an isolated nucleic acid molecule that is a NA Group 3 molecule.

15

70. A method for treating a subject with a disorder characterized by expression of a human cancer associated antigen precursor, comprising

administering to the subject an amount of an agent, which enriches selectively in the subject the presence of complexes of an HLA molecule and a human cancer associated
20 antigen, effective to ameliorate the disorder, wherein the human cancer associated antigen is a fragment of a human cancer associated antigen precursor encoded by a nucleic acid molecule selected from the group consisting of

(a) a nucleic acid molecule comprising NA group 1 nucleic acid molecules,
(b) a nucleic acid molecule comprising NA group 3 nucleic acid molecules,
25 (c) a nucleic acid molecule comprising NA group 5 nucleic acid molecules.

71. The method of claim 70, wherein the disorder is characterized by expression of a plurality of human cancer associated antigen precursors and wherein the agent is a plurality of agents, each of which enriches selectively in the subject the presence of complexes of an HLA
30 molecule and a different human cancer associated antigen, wherein at least one of the human cancer associated antigens is encoded by a NA Group 1 molecule.

72. The method of claim 71, wherein the plurality is at least 2, at least 3, at least 4, or at

least 5 such agents.

73. The method of claims 70-72, wherein the agent is an isolated polypeptide selected from the group consisting of PP Group 1, PP Group 2, PP Group 3, PP Group 4, and PP
5 Group 5.

74. The method of claims 70-72, wherein the disorder is cancer.

75. The method of claims 73, wherein the disorder is cancer.
10

76. A method for treating a subject having a condition characterized by expression of a human cancer associated antigen precursor in cells of the subject, comprising:

(i) removing an immunoreactive cell containing sample from the subject,

(ii) contacting the immunoreactive cell containing sample to the host cell under
15 conditions favoring production of cytolytic T cells against a human cancer associated antigen which is a fragment of the precursor,

(iii) introducing the cytolytic T cells to the subject in an amount effective to lyse cells which express the human cancer associated antigen, wherein the host cell is transformed or transfected with an expression vector comprising an isolated nucleic acid molecule
20 operably linked to a promoter, the isolated nucleic acid molecule being selected from the group of nucleic acid molecules consisting of NA Group 1, NA Group 2, NA Group 3, NA Group 4, and NA Group 5.

77. The method of claim 76, wherein the host cell recombinantly expresses an HLA
25 molecule which binds the human cancer associated antigen.

78. The method of claim 76, wherein the host cell endogenously expresses an HLA molecule which binds the human cancer associated antigen.

79. A method for treating a subject having a condition characterized by expression of a
30 human cancer associated antigen precursor in cells of the subject, comprising:

(i) identifying a nucleic acid molecule expressed by the cells associated with said condition, wherein said nucleic acid molecule is a NA Group 1 molecule;

(ii) transfecting a host cell with a nucleic acid selected from the group consisting

of (a) the nucleic acid molecule identified, (b) a fragment of the nucleic acid identified which includes a segment coding for a human cancer associated antigen, (c) deletions, substitutions or additions to (a) or (b), and (d) degenerates of (a), (b), or (c);

(iii) culturing said transfected host cells to express the transfected nucleic acid
5 molecule, and;

(iv) introducing an amount of said host cells or an extract thereof to the subject effective to increase an immune response against the cells of the subject associated with the condition.

10 80. The method of claim 79, further comprising identifying an MHC molecule which presents a portion of an expression product of the nucleic acid molecule, wherein the host cell expresses the same MHC molecule as identified and wherein the host cell presents an MHC binding portion of the expression product of the nucleic acid molecule.

15 81. The method of claim 79, wherein the immune response comprises a B-cell response or a T cell response.

82. The method of claim 81, wherein the response is a T-cell response which comprises generation of cytolytic T-cells specific for the host cells presenting the portion of the
20 expression product of the nucleic acid molecule or cells of the subject expressing the human cancer associated antigen.

83. The method of claim 79, wherein the nucleic acid molecule is a NA Group 3 molecule.

25 84. The method of claims 79 or 80, further comprising treating the host cells to render them non-proliferative.

85. A method for treating or diagnosing or monitoring a subject having a condition characterized by expression of an abnormal amount of a protein encoded by a nucleic acid
30 molecule that is a NA Group 1 molecule, comprising

administering to the subject an antibody which specifically binds to the protein or a peptide derived therefrom, the antibody being coupled to a therapeutically useful agent, in an amount effective to treat the condition.

86. The method of claim 85, wherein the antibody is a monoclonal antibody.

87. The method of claim 86, wherein the monoclonal antibody is a chimeric antibody or a
5 humanized antibody.

88. A method for treating a condition characterized by expression in a subject of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule, comprising
10 administering to a subject a pharmaceutical composition of any one of claims 13-25 and 37-47 in an amount effective to prevent, delay the onset of, or inhibit the condition in the subject.

89. The method of claim 88, wherein the condition is cancer.
15

90. The method of claim 88, further comprising first identifying that the subject expresses in a tissue abnormal amounts of the protein.

91. The method of claim 89, further comprising first identifying that the subject expresses
20 in a tissue abnormal amounts of the protein.

92. A method for treating a subject having a condition characterized by expression of abnormal amounts of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule, comprising
25 (i) identifying cells from the subject which express abnormal amounts of the protein;
(ii) isolating a sample of the cells;
(iii) cultivating the cells, and
(iv) introducing the cells to the subject in an amount effective to provoke an immune response against the cells.
30

93. The method of claim 92, further comprising rendering the cells non-proliferative, prior to introducing them to the subject.

94. A method for treating a pathological cell condition characterized by aberrant expression of a protein encoded by a nucleic acid molecule that is a NA Group 1 nucleic acid molecule, comprising

administering to a subject in need thereof an effective amount of an agent which
5 inhibits the expression or activity of the protein.

95. The method of claim 94, wherein the agent is an inhibiting antibody which selectively binds to the protein and wherein the antibody is a monoclonal antibody, a chimeric antibody or a humanized antibody.

10

96. The method of claim 94, wherein the agent is an antisense nucleic acid molecule which selectively binds to the nucleic acid molecule which encodes the protein.

97. The method of claim 94, wherein the nucleic acid molecule is a NA Group 3 nucleic
15 acid molecule.

98. A composition of matter useful in stimulating an immune response to a plurality of a proteins encoded by nucleic acid molecules that are NA Group 1 molecules, comprising

a plurality of peptides derived from the amino acid sequences of the proteins, wherein
20 the peptides bind to one or more MHC molecules presented on the surface of the cells which express an abnormal amount of the protein.

99. The composition of matter of claim 98, wherein at least a portion of the plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto.

25

100. The composition of matter of claim 99, further comprising an adjuvant.

101. The composition of matter of claim 100, wherein said adjuvant is a saponin, GM-CSF, or an interleukin.

30

102. The composition of matter of claim 98, further comprising at least one peptide useful in stimulating an immune response to at least one protein which is not encoded by nucleic acid molecules that are NA Group 1 molecules, wherein the at least one peptide binds to one

or more MHC molecules.

103. An isolated antibody which selectively binds to a complex of:

(i) a peptide derived from a protein encoded by a nucleic acid molecule that is a
5 NA Group 1 molecule and

(ii) and an MHC molecule to which binds the peptide to form the complex,
wherein the isolated antibody does not bind to (i) or (ii) alone.

104. The antibody of claim 103, wherein the antibody is a monoclonal antibody, a chimeric
10 antibody, a humanized antibody, or a fragment thereof.

SEQUENCE LISTING

<110> Ludwig Institute for Cancer Research

<120> CANCER ASSOCIATED ANTIGENS AND USES THEREFOR

<130> L0461/7061WO

<140> US 09/320,092
<141> 1999-05-26

<160> 17

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 1242
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> 255..255
<223> n = a, c, g or t

<220>
<221> unsure
<222> 1134..1134
<223> n = a, c, g or t

<220>
<221> unsure
<222> 1137..1137
<223> n = a, c, g or t

<220>
<221> unsure
<222> 1179..1179
<223> n = a, c, g or t

<220>
<221> unsure
<222> 1183..1183
<223> n = a, c, g or t

<400> 1
gtcatgctga agtagtcaat ctccttttgc gacatggtgc agaccccaat gctcgagata 60
attggaatta tactcctctc catgaagctg caattaaagg aaagattgat gtttgcattg 120
tgctgttaca gcatggagct gagccaacca tccgaaatac agatggaagg acagcattgg 180
atttagcaga tccatctgcc aaagcagtgc ttactggtga atataagaaa gatgaactct 240
tagaaagtgc caggngtggc aatgaagaaa aaatgatggc tctactcaca ccattaaatg 300
tcaactgcca cgcaagtgat ggcagaaagt caactccatt acatttggca gcaggatata 360
acagagtaaa gattgtacag ctgttactgc aacatggagc tgatgtccat gctaaagata 420
aaggtgatct ggtaccatta cacaatgcct gttcttatgg tcattatgaa gtaactgaac 480
ttttggtcaa gcatggtgcc tgtgtaaatg caatggactt gtggcaattc actcctcttc 540
atgaggcagc ttctaagaac agggttgaag tatgttctct tctcttaagt tatggtgcag 600
acccaacact gctcaattgt cacaataaaa gtgctataga cttggctccc acaccacagt 660
taaaagaaag attagcatat gaatttaaag gccactcgtt gctgcaagct gcacgagaag 720
ctgatgttac tcgaatcaaa aaacatctct ctctggaaat ggtgaatttc aagcatcctc 780
aaacacatga aacagcattg cattgtgctg ctgcatctcc atatcccaaa agaaagcaaa 840
tatgtgaact gttgctaaga aaaggagcaa acatcaatga aaagactaaa gaattcttga 900

```
ctcctctgca cgtggcatct gagaaagctc ataatgatgt tgttgaagta gtggtgaaac     960
atgaagcaaa ggttaatgct ctggataatc ttggtcagac ttctctacac agagctgcat    1020
attgtggtca tctacacacc tgccgcctac tcctgagcta tgggtgtgat cctaacatta    1080
tatcccttca gggctttact gctttacaga tgggaatgaa atgtacagca actnctncaa    1140
gagggtatct cattaggtaa ttcagaggca gacagacant ttnctggtaa gctgcaaagg    1200
ctgagatgtc gaactctaaa aaactgtgta ctgttcagag tg                       1242

      <210> 2
      <211> 385
      <212> PRT
      <213> Homo sapiens

      <220>
      <221> UNSURE
      <222> 85..85
      <223> Xaa = any amino acid

      <220>
      <221> UNSURE
      <222> 378..379
      <223> Xaa = any amino acid

      <400> 2
His Ala Glu Val Val Asn Leu Leu Leu Arg His Gly Ala Asp Pro Asn
 1               5                  10                  15
Ala Arg Asp Asn Trp Asn Tyr Thr Pro Leu His Glu Ala Ala Ile Lys
            20                  25                  30
Gly Lys Ile Asp Val Cys Ile Val Leu Leu Gln His Gly Ala Glu Pro
        35                  40                  45
Thr Ile Arg Asn Thr Asp Gly Arg Thr Ala Leu Asp Leu Ala Asp Pro
    50                  55                  60
Ser Ala Lys Ala Val Leu Thr Gly Glu Tyr Lys Lys Asp Glu Leu Leu
65                  70                  75                  80
Glu Ser Ala Arg Xaa Gly Asn Glu Glu Lys Met Met Ala Leu Leu Thr
                85                  90                  95
Pro Leu Asn Val Asn Cys His Ala Ser Asp Gly Arg Lys Ser Thr Pro
            100                 105                 110
Leu His Leu Ala Ala Gly Tyr Asn Arg Val Lys Ile Val Gln Leu Leu
        115                 120                 125
Leu Gln His Gly Ala Asp Val His Ala Lys Asp Lys Gly Asp Leu Val
    130                 135                 140
Pro Leu His Asn Ala Cys Ser Tyr Gly His Tyr Glu Val Thr Glu Leu
145                 150                 155                 160
Leu Val Lys His Gly Ala Cys Val Asn Ala Met Asp Leu Trp Gln Phe
                165                 170                 175
Thr Pro Leu His Glu Ala Ala Ser Lys Asn Arg Val Glu Val Cys Ser
            180                 185                 190
Leu Leu Leu Ser Tyr Gly Ala Asp Pro Thr Leu Leu Asn Cys His Asn
        195                 200                 205
Lys Ser Ala Ile Asp Leu Ala Pro Thr Pro Gln Leu Lys Glu Arg Leu
    210                 215                 220
Ala Tyr Glu Phe Lys Gly His Ser Leu Leu Gln Ala Ala Arg Glu Ala
225                 230                 235                 240
Asp Val Thr Arg Ile Lys Lys His Leu Ser Leu Glu Met Val Asn Phe
                245                 250                 255
Lys His Pro Gln Thr His Glu Thr Ala Leu His Cys Ala Ala Ala Ser
            260                 265                 270
Pro Tyr Pro Lys Arg Lys Gln Ile Cys Glu Leu Leu Leu Arg Lys Gly
        275                 280                 285
Ala Asn Ile Asn Glu Lys Thr Lys Glu Phe Leu Thr Pro Leu His Val
    290                 295                 300
```

```
Ala Ser Glu Lys Ala His Asn Asp Val Val Glu Val Val Val Lys His
305                 310                 315                 320
Glu Ala Lys Val Asn Ala Leu Asp Asn Leu Gly Gln Thr Ser Leu His
                325                 330                 335
Arg Ala Ala Tyr Cys Gly His Leu His Thr Cys Arg Leu Leu Leu Ser
            340                 345                 350
Tyr Gly Cys Asp Pro Asn Ile Ile Ser Leu Gln Gly Phe Thr Ala Leu
        355                 360                 365
Gln Met Gly Met Lys Cys Thr Ala Thr Xaa Xaa Arg Gly Tyr Leu Ile
    370                 375                 380
Arg
385
```

```
<210> 3
<211> 1089
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> 53..53
<223> n = a, c, g or t

<220>
<221> unsure
<222> 58..58
<223> n = a, c, g or t

<220>
<221> unsure
<222> 99..99
<223> n = a, c, g or t

<220>
<221> unsure
<222> 139..139
<223> n = a, c, g or t

<220>
<221> unsure
<222> 158..158
<223> n = a, c, g or t

<220>
<221> unsure
<222> 242..242
<223> n = a, c, g or t

<220>
<221> unsure
<222> 244..244
<223> n = a, c, g or t

<220>
<221> unsure
<222> 261..261
<223> n = a, c, g or t

<220>
<221> unsure
<222> 280..280
```

<223> n = a, c, g or t

<220>
<221> unsure
<222> 282..282
<223> n = a, c, g or t

<220>
<221> unsure
<222> 345..345
<223> n = a, c, g or t

<220>
<221> unsure
<222> 348..348
<223> n = a, c, g or t

<220>
<221> unsure
<222> 1054..1054
<223> n = a, c, g or t

<220>
<221> unsure
<222> 1068..1068
<223> n = a, c, g or t

<220>
<221> unsure
<222> 1086..1086
<223> n = a, c, g or t

<220>
<221> unsure
<222> 1089..1089
<223> n = a, c, g or t

<400> 3
tttacaagtg aacagtttta ttaagaatta aatgagggta tggaatttga tanagtanaa 60
gtaagacact gaagatgggt ataatagtac tacttgcana aaaagttaaa tttcacttca 120
aaaaaaaaaa tcacaagana aaagaaaaag caattccntc attataaagt aagctatttc 180
atgcaacgta ctaatactcc ccctcccccc aaaaccccaa cttcccaaca aacaaaaagc 240
tntntgaaaa tgctgccatg ntaacatatg acccacggtn tnttcattca tggaaaaaca 300
cactcattaa gcaatggttt agataaaata acacagtatg cagtnttnta aactcatagc 360
ccacaatgtt ttcacatgaa aagcaattcc agattcactc atagggtgag taatatgggc 420
tacatagttg agagataatg taaatataaa ccccattaat tctctcatta tcttctaatt 480
ataaaacctg ggagcttaga taatctgaaa aattcatata aaatttggca tactccactt 540
gtgttccaag aaatgacttt cggatatttg taattattag agagctgtat aaaaagcact 600
tcaagatcag gatttgactt cttaaataat gatcataatt tacatcacag aaacaactcc 660
agaaatgcac ttactctgat taactcttac tcaggacaag gaacatgatt ttctagcact 720
ttatgtacaa gttactgcaa agggccagtt aatttacaga ctgaataaaa cgtaaaataa 780
aggtgaactg gtacagacag tgatggggaa tgtcctcatt aagtgagtaa agatctttcc 840
tcgactttga agggagctag agtcaacaaa taaaagagat tgccaagcca taatggatgt 900
atgtctctgt aacaagatgc ttaagcatgc ttcctggaaa agagtgttat attagaaata 960
gggatggcat tttatgggac agcatttcct tctatagctg ccaactgagc acaggcgtgg 1020
tcaccatatg gtgcacaaac tgacagcata tttnccaatt ggggcatnaa catccatggg 1080
ggaggnaan 1089

<210> 4
<211> 1007
<212> DNA

<213> Homo sapiens

<400> 4

```
aagtaactga acttttggtc aagcatggtg cctgtgtaaa tgcaatggac ttgtggcaat      60
tcactcctct tcatgaggca gcttctaaga acagggttga agtatgttct cttctcttaa     120
gttatggtgc agacccaaca ctgctcaatt gtcacaataa aagtgctata gacttggctc     180
ccacaccaca gttaaaagaa agattagcat atgaatttaa aggccactcg ttgctgcaag     240
ctgcacgaga agctgatgtt actcgaatca aaaaacatct ctctctggaa atggtgaatt     300
tcaagcatcc tcaaacacat gaaacagcat tgcattgtgc tgctgcatct ccatatccca     360
aaagaaagca aatatgtgaa ctgttgctaa aaaaaggatc aaacatcaat gaaaagacta     420
aagaattctt gactcctctg cacgtggcat ctgagaaagc tcataatgat gttgttgaag     480
tagtggtgaa acatgaagca aaggttaatg ctctggataa tcttggtcag acttctctac     540
acagagctgc atattgtggt catctacaaa cctgccgcct actcctgagc tatgggtgtg     600
atcctaacat tatatccctt cagggcttta ctgctttaca gatgggaaat gaaaatgtac     660
agcaactcct ccaagagggt atctcattag gtaattcaga ggcagacaga caattgctgg     720
aagctgcaaa ggctggagat gtcaaaactg taaaaaaact gtgtactgtt cagagtgtca     780
actgcagaga cattgaaggg cgtcagtcta caccacttca ttttgcagct gggtataaca     840
gagtgtccgt ggtggaatat ctgctacagc atggagctga tgtgcatgct aaagagaaag     900
gaggccttgt acctttgcac aatgcatgtt cttatggaca ttatgaagtt gcagaacttc     960
ttgttaaaca tggagcagta ttcaatgtta ccgaattatg gaaattc                  1007
```

<210> 5
<211> 331
<212> PRT
<213> Homo sapiens

<400> 5

```
Leu Val Lys His Gly Ala Cys Val Asn Ala Met Asp Leu Trp Gln Phe
1               5                   10                  15
Thr Pro Leu His Glu Ala Ala Ser Lys Asn Arg Val Glu Val Cys Ser
            20                  25                  30
Leu Leu Leu Ser Tyr Gly Ala Asp Pro Thr Leu Leu Asn Cys His Asn
        35                  40                  45
Lys Ser Ala Ile Asp Leu Ala Pro Thr Pro Gln Leu Lys Glu Arg Leu
    50                  55                  60
Ala Tyr Glu Phe Lys Gly His Ser Leu Leu Gln Ala Ala Arg Glu Ala
65                  70                  75                  80
Asp Val Thr Arg Ile Lys Lys His Leu Ser Leu Glu Met Val Asn Phe
                85                  90                  95
Lys His Pro Gln Thr His Glu Thr Ala Leu His Cys Ala Ala Ala Ser
            100                 105                 110
Pro Tyr Pro Lys Arg Lys Gln Ile Cys Glu Leu Leu Leu Lys Lys Gly
        115                 120                 125
Ser Asn Ile Asn Glu Lys Thr Lys Glu Phe Leu Thr Pro Leu His Val
    130                 135                 140
Ala Ser Glu Lys Ala His Asn Asp Val Val Glu Val Val Val Lys His
145                 150                 155                 160
Glu Ala Lys Val Asn Ala Leu Asp Asn Leu Gly Gln Thr Ser Leu His
                165                 170                 175
Arg Ala Ala Tyr Cys Gly His Leu Gln Thr Cys Arg Leu Leu Leu Ser
            180                 185                 190
Tyr Gly Cys Asp Pro Asn Ile Ile Ser Leu Gln Gly Phe Thr Ala Leu
        195                 200                 205
Gln Met Gly Asn Glu Asn Val Gln Gln Leu Leu Gln Glu Gly Ile Ser
    210                 215                 220
Leu Gly Asn Ser Glu Ala Asp Arg Gln Leu Leu Glu Ala Ala Lys Ala
225                 230                 235                 240
Gly Asp Val Lys Thr Val Lys Lys Leu Cys Thr Val Gln Ser Val Asn
                245                 250                 255
Cys Arg Asp Ile Glu Gly Arg Gln Ser Thr Pro Leu His Phe Ala Ala
            260                 265                 270
```

```
Gly Tyr Asn Arg Val Ser Val Val Glu Tyr Leu Leu Gln His Gly Ala
        275                 280                 285
Asp Val His Ala Lys Glu Lys Gly Gly Leu Val Pro Leu His Asn Ala
    290                 295                 300
Cys Ser Tyr Gly His Tyr Glu Val Ala Glu Leu Leu Val Lys His Gly
305                 310                 315                 320
Ala Val Phe Asn Val Thr Glu Leu Trp Lys Phe
                325                 330

      <210> 6
      <211> 567
      <212> DNA
      <213> Homo sapiens

      <400> 6
ttttttttt ttttttttt ttttttttt ttttttttt ttttttacaa gtgaacagtt      60
ttattaagaa ttaaatgagg gtatggaatt tgatacagta caagtaagac actgaagatg   120
ggtataatag tactactggc acaaaaagtt aaatttcact tcaaaaaaaa aaatcccaaa   180
acaaaagaaa aagcattccc atcattataa agtaggctat tccatgcaac gtactaatac   240
tccccctccc cccaaaaccc caacttccca acaaacaaaa agctatctga aaatgctgcc   300
atgctaacat atgaaccacg gtatattcat tcatggaaaa acacactcat taagcaatgg   360
tttagataaa ataacacagt ttgcagtatt gtaaactcat agaccacaat gatttcacat   420
gaaaagcaat tccagattca ctcatagggt gagtaatatg ggctacatag ttgagagata   480
atgtaaatat aaaccccatt aattctctca ttatcttcta attataaaac ctgggagctt   540
agataatctg aaaaattcat ataaaat                                       567

      <210> 7
      <211> 2312
      <212> DNA
      <213> Homo sapiens

      <400> 7
gttccagaat gattttgaaa aagcttgtca agcaaaatct gaagctctcg ttcttcggga      60
aaagagtacc cttgaaagaa ttcacaagca ccaagagatt gaaacaaaag aaatttatgc   120
tcaaaggcaa cttttactaa aagatatgga tttgctaaga ggaagagaag cagagctgaa   180
gcaaagagtt gaagcttttg aattgaacca gaagctccag gaagaaaaac ataaaagcat   240
aactgaggca cttaggagac aggagcagaa tataaagagt tttgaggaga cctatgaccg   300
aaagctcaag aatgaacttc taaagtatca acttgaactg aaggatgact acatcattag   360
aactaatcga ctgattgaag atgaaaggaa gaataaagaa aaagctgttc atttgcaaga   420
ggagctcata gctattaatt caaaaaagga ggaactcaat caatctgtaa atcgtgtgaa   480
agaacttgag cttgaattag agtctgtcaa agcccagtct ttggcaataa caaaacaaaa   540
ccatatgctg aatgaaaagg ttaaagagat gagtgattat tcactactaa aagaagagaa   600
actggagctt ctggcacaaa ataaattact taaacaacaa ctggaagaga gtagaaatga   660
aaacctgcgt ctcctaaacc gcctagctca gccggctcct gaacttgcag tctttcagaa   720
agaactacgg aaagccgaaa aggctatagt ggttgagcat gaggagttcg aaagctgcag   780
gcaagctctg cacaaacaac tgcaagacga aattgagcat tctgcacagc tgaaggccca   840
gattctaggt tacaaagctt ctgtaaagag tttaactact caggttgccg atttaaaatt   900
gcaactgaag caaactcaga cagccctaga gaatgaagtg tactgcaatc caaagcagtc   960
tgtgatcgat cgttctgtca atggattaat aaatggcaat gtggtgcctt gcaatggtga  1020
gataagtggg gatttcttga acaatccttt taaacaggaa aacgttctag cacgtatggt  1080
tgcatcaagg atcacaaatt atccaactgc atgggtggag ggtagttccc ctgattctga  1140
ccttgagttt gtagccaata ctaaggcaag ggtcaaagag cttcagcaag aggccgaacg  1200
cttggaaaag gctttcagaa gttaccatcg gagagtcatt aaaaactctg ccaaaagccc  1260
actagcagca aagagcccac catctctgca cttgctggaa gccttcaaaa acattacttc  1320
cagttccccg gaaagacata tttttggaga ggacagagtt gtctctgagc agcctcaagt  1380
gggcacactt gaagaaagga atgacgtcgt ggaagcactg acaggcagtg cagcctcgag  1440
gctccgcggg ggcacttcct ccagacgcct ctcttccaca ccccttccaa aagcaaaaag  1500
aagcctcgaa agtgaaatgt atctggaagg tctgggcaga tcacacattg cttcccccag  1560
tccttgtcct gacagaatgc ccctaccatc acccactgag tctaggcaca gcctctccat  1620
ccctcctgtc tccagccctc cggagcagaa agtgggtctt tatcgaagac aaactgaact  1680
tcaagacaaa agtgaatttt cagatgtgga caagctagct tttaaggata atgaggagtt  1740
```

```
tgaatcatct tttgaatgtg tagatcagaa acaaattgaa gaacaaaagg aagaagaaaa    1800
aatacgggaa cagcaagtga aagaacgaag gcagagagaa gaaagaaggc agagtaacct    1860
acaagaagtt ttagaaaggg aacgaagaga actagaaaaa ctgtatcagg aaaggaagat    1920
gattgaagaa tcactgaaga ttaaaataaa aaaggaatta gaaatggaaa atgaattaga    1980
aatgagtaat caagaaataa aagacaaatc tgctcacagt gaaaatcctt tagagaaata    2040
catgaaaatc atccagcagg agcaagacca ggagtcggca gataagagct caaaaaagat    2100
ggtccaagaa ggctccctag tggacacgct gcaatctagt gacaaagtcg aaagtttaac    2160
aggcttttct catgaagaac tagacgactc ttggtaacca tgtttgctgc ccagcttcta    2220
acttacatac cgtgagaagt tacgtaacat ttactccttt gtaaatgttt ccctatcatc    2280
agacaaaact caataaaaat gtgtgtaatc cc                                  2312
```

<210> 8
<211> 731
<212> PRT
<213> Homo sapiens

<400> 8

```
Phe Gln Asn Asp Phe Glu Lys Ala Cys Gln Ala Lys Ser Glu Ala Leu
1               5                   10                  15
Val Leu Arg Glu Lys Ser Thr Leu Glu Arg Ile His Lys His Gln Glu
            20                  25                  30
Ile Glu Thr Lys Glu Ile Tyr Ala Gln Arg Gln Leu Leu Leu Lys Asp
        35                  40                  45
Met Asp Leu Leu Arg Gly Arg Glu Ala Glu Leu Lys Gln Arg Val Glu
    50                  55                  60
Ala Phe Glu Leu Asn Gln Lys Leu Gln Glu Glu Lys His Lys Ser Ile
65                  70                  75                  80
Thr Glu Ala Leu Arg Arg Gln Glu Gln Asn Ile Lys Ser Phe Glu Glu
                85                  90                  95
Thr Tyr Asp Arg Lys Leu Lys Asn Glu Leu Leu Lys Tyr Gln Leu Glu
            100                 105                 110
Leu Lys Asp Asp Tyr Ile Ile Arg Thr Asn Arg Leu Ile Glu Asp Glu
        115                 120                 125
Arg Lys Asn Lys Glu Lys Ala Val His Leu Gln Glu Glu Leu Ile Ala
    130                 135                 140
Ile Asn Ser Lys Lys Glu Glu Leu Asn Gln Ser Val Asn Arg Val Lys
145                 150                 155                 160
Glu Leu Glu Leu Glu Leu Glu Ser Val Lys Ala Gln Ser Leu Ala Ile
                165                 170                 175
Thr Lys Gln Asn His Met Leu Asn Glu Lys Val Lys Glu Met Ser Asp
            180                 185                 190
Tyr Ser Leu Leu Lys Glu Glu Lys Leu Glu Leu Leu Ala Gln Asn Lys
        195                 200                 205
Leu Leu Lys Gln Gln Leu Glu Glu Ser Arg Asn Glu Asn Leu Arg Leu
    210                 215                 220
Leu Asn Arg Leu Ala Gln Pro Ala Pro Glu Leu Ala Val Phe Gln Lys
225                 230                 235                 240
Glu Leu Arg Lys Ala Glu Lys Ala Ile Val Val Glu His Glu Glu Phe
                245                 250                 255
Glu Ser Cys Arg Gln Ala Leu His Lys Gln Leu Gln Asp Glu Ile Glu
            260                 265                 270
His Ser Ala Gln Leu Lys Ala Gln Ile Leu Gly Tyr Lys Ala Ser Val
        275                 280                 285
Lys Ser Leu Thr Thr Gln Val Ala Asp Leu Lys Leu Gln Leu Lys Gln
    290                 295                 300
Thr Gln Thr Ala Leu Glu Asn Glu Val Tyr Cys Asn Pro Lys Gln Ser
305                 310                 315                 320
Val Ile Asp Arg Ser Val Asn Gly Leu Ile Asn Gly Asn Val Val Pro
                325                 330                 335
Cys Asn Gly Glu Ile Ser Gly Asp Phe Leu Asn Asn Pro Phe Lys Gln
            340                 345                 350
```

```
Glu Asn Val Leu Ala Arg Met Val Ala Ser Arg Ile Thr Asn Tyr Pro
        355                 360                 365
Thr Ala Trp Val Glu Gly Ser Ser Pro Asp Ser Asp Leu Glu Phe Val
    370                 375                 380
Ala Asn Thr Lys Ala Arg Val Lys Glu Leu Gln Gln Glu Ala Glu Arg
385                 390                 395                 400
Leu Glu Lys Ala Phe Arg Ser Tyr His Arg Arg Val Ile Lys Asn Ser
                405                 410                 415
Ala Lys Ser Pro Leu Ala Ala Lys Ser Pro Pro Ser Leu His Leu Leu
            420                 425                 430
Glu Ala Phe Lys Asn Ile Thr Ser Ser Ser Pro Glu Arg His Ile Phe
        435                 440                 445
Gly Glu Asp Arg Val Val Ser Glu Gln Pro Gln Val Gly Thr Leu Glu
    450                 455                 460
Glu Arg Asn Asp Val Val Glu Ala Leu Thr Gly Ser Ala Ala Ser Arg
465                 470                 475                 480
Leu Arg Gly Gly Thr Ser Ser Arg Arg Leu Ser Ser Thr Pro Leu Pro
                485                 490                 495
Lys Ala Lys Arg Ser Leu Glu Ser Glu Met Tyr Leu Glu Gly Leu Gly
            500                 505                 510
Arg Ser His Ile Ala Ser Pro Ser Pro Cys Pro Asp Arg Met Pro Leu
        515                 520                 525
Pro Ser Pro Thr Glu Ser Arg His Ser Leu Ser Ile Pro Pro Val Ser
    530                 535                 540
Ser Pro Pro Glu Gln Lys Val Gly Leu Tyr Arg Arg Gln Thr Glu Leu
545                 550                 555                 560
Gln Asp Lys Ser Glu Phe Ser Asp Val Asp Lys Leu Ala Phe Lys Asp
                565                 570                 575
Asn Glu Glu Phe Glu Ser Ser Phe Glu Cys Val Asp Gln Lys Gln Ile
            580                 585                 590
Glu Glu Gln Lys Glu Glu Glu Lys Ile Arg Glu Gln Gln Val Lys Glu
        595                 600                 605
Arg Arg Gln Arg Glu Glu Arg Arg Gln Ser Asn Leu Gln Glu Val Leu
    610                 615                 620
Glu Arg Glu Arg Arg Glu Leu Glu Lys Leu Tyr Gln Glu Arg Lys Met
625                 630                 635                 640
Ile Glu Glu Ser Leu Lys Ile Lys Ile Lys Lys Glu Leu Glu Met Glu
                645                 650                 655
Asn Glu Leu Glu Met Ser Asn Gln Glu Ile Lys Asp Lys Ser Ala His
            660                 665                 670
Ser Glu Asn Pro Leu Glu Lys Tyr Met Lys Ile Ile Gln Gln Glu Gln
        675                 680                 685
Asp Gln Glu Ser Ala Asp Lys Ser Ser Lys Lys Met Val Gln Glu Gly
    690                 695                 700
Ser Leu Val Asp Thr Leu Gln Ser Ser Asp Lys Val Glu Ser Leu Thr
705                 710                 715                 720
Gly Phe Ser His Glu Glu Leu Asp Asp Ser Trp
                725                 730
```

<210> 9
<211> 5005
<212> DNA
<213> Homo sapiens

<220>
<221> unsure
<222> 3838..3838
<223> n = a, c, g or t

<220>
<221> unsure

```
<222> 3840..3840
<223> n = a, c, g or t

<220>
<221> unsure
<222> 3842..3842
<223> n = a, c, g or t

<220>
<221> unsure
<222> 3846..3846
<223> n = a, c, g or t

<220>
<221> unsure
<222> 3850..3850
<223> n = a, c, g or t

<220>
<221> unsure
<222> 3882..3882
<223> n = a, c, g or t

<220>
<221> unsure
<222> 3916..3916
<223> n = a, c, g or t

<220>
<221> unsure
<222> 3930..3930
<223> n = a, c, g or t

<220>
<221> unsure
<222> 3931..3931
<223> n = a, c, g or t

<220>
<221> unsure
<222> 3955..3955
<223> n = a, c, g or t

<400> 9
aagtaactga acttttggtc aagcatggtg cctgtgtaaa tgcaatggac ttgtggcaat      60
tcactcctct tcatgaggca gcttctaaga acagggttga agtatgttct cttctcttaa     120
gttatggtgc agacccaaca ctgctcaatt gtcacaataa aagtgctata gacttggctc     180
ccacaccaca gttaaaagaa agattagcat atgaatttaa aggccactcg ttgctgcaag     240
ctgcacgaga agctgatgtt actcgaatca aaaaacatct ctctctggaa atggtgaatt     300
tcaagcatcc tcaaacacat gaaacagcat tgcattgtgc tgctgcatct ccatatccca     360
aaagaaagca aatatgtgaa ctgttgctaa aaaaaggatc aaacatcaat gaaaagacta     420
aagaattctt gactcctctg cacgtggcat ctgagaaagc tcataatgat gttgttgaag     480
tagtggtgaa acatgaagca aaggttaatg ctctggataa tcttggtcag acttctctac     540
acagagctgc atattgtggt catctacaaa cctgccgcct actcctgagc tatgggtgtg     600
atcctaacat tatatccctt cagggcttta ctgctttaca gatgggaaat gaaaatgtac     660
agcaactcct ccaagagggt atctcattag gtaattcaga ggcagacaga caattgctgg     720
aagctgcaaa ggctggagat gtcgaaactg taaaaaaact gtgtactgtt cagagtgtca     780
actgcagaga cattgaaggg cgtcagtcta caccacttca ttttgcagct gggtataaca     840
gagtgtccgt ggtggaatat ctgctacagc atggagctga tgtgcatgct aaagataaag     900
gaggccttgt acctttgcac aatgcatgtt cttatggaca ttatgaagtt gcagaacttc     960
ttgttaaaca tggagcagta gttaatgtag ctgatttatg gaaatttaca cctttacatg    1020
```

```
aagcagcagc aaaaggaaaa tatgaaattt gcaaacttct gctccagcat ggtgcagacc    1080
ctacaaaaaa aaacagggat ggaaatactc ctttggatct tgttaaagat ggagatacag    1140
atattcaaga tctgcttagg ggagatgcag ctttgctaga tgctgccaag aagggttgtt    1200
tagccagagt gaagaagttg tcttctcctg ataatgtaaa ttgccgcgat acccaaggca    1260
gacattcaac acctttacat ttagcagctg gttataataa tttagaagtt gcagagtatt    1320
tgttacaaca cggagctgat gtgaatgccc aagacaaagg aggacttatt cctttacata    1380
atgcagcatc ttacgggcat gtagatgtag cagctctact aataaagtat aatgcatgtg    1440
tcaatgccac ggacaaatgg gctttcacac ctttgcacga agcagcccaa aagggacgaa    1500
cacagctttg tgctttgttg ctagcccatg gagctgaccc gactcttaaa aatcaggaag    1560
gacaaacacc tttagattta gtttcagcag atgatgtcag cgctcttctg acagcagcca    1620
tgcccccatc tgctctgccc tcttgttaca agcctcaagt gctcaatggt gtgagaagcc    1680
caggagccac tgcagatgct ctctttcagg tccatctagc ccatcaagcc tttctgcagc    1740
cagcagtctt gacaactatc tgggagtttt cagaactgtc ttcagtagtt agttcaagtg    1800
gaacagaggg tgcttccagt ttggagaaaa aggaggttcc aggagtagat tttagcataa    1860
ctcaattcgt aaggaatctt ggacttgagc acctaatgga tatatttgag agagaacaga    1920
tcactttgga tgtattagtt gagatggggc acaaggagct gaaggagatt ggaatcaatg    1980
cttatggaca taggcacaaa ctaattaaag gagtcgagag acttatctcc ggacaacaag    2040
gtcttaaccc atatttaact ttgaacacct ctggtagtgg aacaattctt atagatctgt    2100
ctcctgatga taaagagttt cagtctgtgg aggaagagat gcaaagtaca gttcgagagc    2160
acagagatgg aggtcatgca ggtggaatct tcaacagata caatattctc aagattcaga    2220
aggtttgtaa caagaaacta tgggaaagat acactcaccg gagaaaagaa gtttctgaag    2280
aaaaccacaa ccatgccaat gaacgaatgc tatttcatgg gtctcctttt gtgaatgcaa    2340
ttatccacaa aggctttgat gaaaggcatg cgtacatagg tggtatgttt ggagctggca    2400
tttattttgc tgaaaactct tccaaaagca atcaatatgt atatggaatt ggaggaggta    2460
ctgggtgtcc agttcacaaa gacagatctt gttacatttg ccacaggcag ctgctctttt    2520
gccgggtaac cttgggaaag tctttcctgc agttcagtgc aatgaaaatg gcacattctc    2580
ctccaggtca tcactcagtc actggtaggc ccagtgtaaa tggcctagca ttagctgaat    2640
atgttattta cagaggagaa caggcttatc ctgagtattt aattacttac cagattatga    2700
ggcctgaagg tatggtcgat ggataaatag ttattttaag aaactaattc cactgaacct    2760
aaaatcatca aagcagcagt ggcctctacg ttttactcct ttgctgaaaa aaaatcatct    2820
tgcccacagg cctgtggcaa aggataaaaa atgtgaacga agtttaacat tctgacttga    2880
taaagcttta ataatgtaca gtgttttcta aatatttcct gtttttttcag cactttaaca    2940
gatgccattc caggttaaac tgggttgtct gtactaaatt ataaacagag ttaacttgaa    3000
ccttttatat gttatgcatt gattctaaca aactgtaatg ccctcaacag aactaatttt    3060
actaatacaa tactgtgttc tttaaaacac agcatttaca ctgaatacaa tttcatttgt    3120
aaaactgtaa ataagagctt ttgtactagc ccagtattta tttacattgc tttgtaatat    3180
aaatctgttt tagaactgca gcggtttaca aaattttttc atatgtattg ttcatctata    3240
cttcatctta catcgtcatg attgagtgat ctttacattt gattccagag gctatgttca    3300
gttgttagtt gggaaagatt gagttatcag atttaatttg ccgatgggag cctttatctg    3360
tcattagaaa tctttctcat ttaagaactt atgaatatgc tgaagattta atttgtgata    3420
cctttgtatg tatgagacac attccaaaga gctctaacta tgataggtcc tgattactaa    3480
agaagcttct ttactggcct caatttctag ctttcatgtt ggaaaatttt ctgcagtcct    3540
tctgtgaaaa ttagagcaaa gtgctcctgt tttttagaga aactaaatct tgctgttgaa    3600
caattattgt gttcttttca tggaacataa gtaggatgtt aacatttcca gggtgggaag    3660
ggtaatccta aatcatttcc caatctattc taattacctt aaatctaaag gggaaaaaaa    3720
aaatcacaaa caggactggg tagttttttta tcctaagtat attttttcct gttcttttta    3780
cttggtttta ttgctgtatt tatagccaat ctatacatca tggggtaaac ttaacccngn    3840
antatnaaan gtagttgttt cagtcccctt caggcctcct gnatgggcaa gtgcagtgaa    3900
acaggtgctt cctggntcct gggttttctn ntccatgatg ttatgcccaa ttggnaaata    3960
tgctgtcagt ttgtgcacca tatggtgacc acgcctgtgc tcagttggca gctatagaag    4020
gaaatgctgt cccataaaat gccatcccta tttctaatat aacactcttt tccaggaagc    4080
atgcttaagc atcttgttac agagacatac atccattatg gcttggcaat ctcttttatt    4140
tgttgactct agctcccttc aaagtcgagg aaagatcttt actcacttaa tgaggacatt    4200
ccccatcact gtctgtacca gttcaccttt attttacgtt ttattcagtc tgtaaattaa    4260
ctggcccttt gcagtaactt gtacataaag tgctagaaaa tcatgttcct tgtcctgagt    4320
aagagttaat cagagtaagt gcatttctgg agttgtttct gtgatgtaaa ttatgatcat    4380
tatttaagaa gtcaaatcct gatcttgaag tgctttttat acagctctct aataattaca    4440
aatatccgaa agtcatttct tggaacacaa gtggagtatg ccaaatttta tatgaatttt    4500
tcagattatc taagcttcca ggttttataa ttagaagata atgagagaat taatggggtt    4560
tatatttaca ttatctctca actatgtagc ccatattact caccctatga gtgaatctgg    4620
aattgctttt catgtgaaat cattgtggtc tatgagttta caatactgca aactgtgtta    4680
```

```
ttttatctaa accattgctt aatgagtgtg tttttccatg aatgaatata ccgtggttca    4740
tatgttagca tggcagcatt ttcagatagc tttttgtttg ttgggaagtt ggggttttgg    4800
ggggaggggg agtattagta cgttgcatgg aatagcctac tttataatga tgggaatgct    4860
ttttcttttg ttttgggatt tttttttttg aagtgaaatt taactttttg tgccagtagt    4920
actattatac ccatcttcag tgtcttactt gtactgtatc aaattccata ccctcattta    4980
attcttaata aaactgttca cttgt                                          5005

      <210> 10
      <211> 907
      <212> PRT
      <213> Homo sapiens

      <400> 10
Val Thr Glu Leu Leu Val Lys His Gly Ala Cys Val Asn Ala Met Asp
1               5                   10                  15
Leu Trp Gln Phe Thr Pro Leu His Glu Ala Ala Ser Lys Asn Arg Val
            20                  25                  30
Glu Val Cys Ser Leu Leu Leu Ser Tyr Gly Ala Asp Pro Thr Leu Leu
        35                  40                  45
Asn Cys His Asn Lys Ser Ala Ile Asp Leu Ala Pro Thr Pro Gln Leu
    50                  55                  60
Lys Glu Arg Leu Ala Tyr Glu Phe Lys Gly His Ser Leu Leu Gln Ala
65                  70                  75                  80
Ala Arg Glu Ala Asp Val Thr Arg Ile Lys Lys His Leu Ser Leu Glu
                85                  90                  95
Met Val Asn Phe Lys His Pro Gln Thr His Glu Thr Ala Leu His Cys
            100                 105                 110
Ala Ala Ala Ser Pro Tyr Pro Lys Arg Lys Gln Ile Cys Glu Leu Leu
        115                 120                 125
Leu Lys Lys Gly Ser Asn Ile Asn Glu Lys Thr Lys Glu Phe Leu Thr
    130                 135                 140
Pro Leu His Val Ala Ser Glu Lys Ala His Asn Asp Val Val Glu Val
145                 150                 155                 160
Val Val Lys His Glu Ala Lys Val Asn Ala Leu Asp Asn Leu Gly Gln
                165                 170                 175
Thr Ser Leu His Arg Ala Ala Tyr Cys Gly His Leu Gln Thr Cys Arg
            180                 185                 190
Leu Leu Leu Ser Tyr Gly Cys Asp Pro Asn Ile Ile Ser Leu Gln Gly
        195                 200                 205
Phe Thr Ala Leu Gln Met Gly Asn Glu Asn Val Gln Gln Leu Leu Gln
    210                 215                 220
Glu Gly Ile Ser Leu Gly Asn Ser Glu Ala Asp Arg Gln Leu Leu Glu
225                 230                 235                 240
Ala Ala Lys Ala Gly Asp Val Glu Thr Val Lys Lys Leu Cys Thr Val
                245                 250                 255
Gln Ser Val Asn Cys Arg Asp Ile Glu Gly Arg Gln Ser Thr Pro Leu
            260                 265                 270
His Phe Ala Ala Gly Tyr Asn Arg Val Ser Val Val Glu Tyr Leu Leu
        275                 280                 285
Gln His Gly Ala Asp Val His Ala Lys Asp Lys Gly Gly Leu Val Pro
    290                 295                 300
Leu His Asn Ala Cys Ser Tyr Gly His Tyr Glu Val Ala Glu Leu Leu
305                 310                 315                 320
Val Lys His Gly Ala Val Val Asn Val Ala Asp Leu Trp Lys Phe Thr
                325                 330                 335
Pro Leu His Glu Ala Ala Ala Lys Gly Lys Tyr Glu Ile Cys Lys Leu
            340                 345                 350
Leu Leu Gln His Gly Ala Asp Pro Thr Lys Lys Asn Arg Asp Gly Asn
        355                 360                 365
Thr Pro Leu Asp Leu Val Lys Asp Gly Asp Thr Asp Ile Gln Asp Leu
    370                 375                 380
```

```
Leu Arg Gly Asp Ala Ala Leu Leu Asp Ala Ala Lys Lys Gly Cys Leu
385                 390                 395                 400
Ala Arg Val Lys Lys Leu Ser Ser Pro Asp Asn Val Asn Cys Arg Asp
                405                 410                 415
Thr Gln Gly Arg His Ser Thr Pro Leu His Leu Ala Ala Gly Tyr Asn
            420                 425                 430
Asn Leu Glu Val Ala Glu Tyr Leu Leu Gln His Gly Ala Asp Val Asn
        435                 440                 445
Ala Gln Asp Lys Gly Gly Leu Ile Pro Leu His Asn Ala Ala Ser Tyr
    450                 455                 460
Gly His Val Asp Val Ala Ala Leu Leu Ile Lys Tyr Asn Ala Cys Val
465                 470                 475                 480
Asn Ala Thr Asp Lys Trp Ala Phe Thr Pro Leu His Glu Ala Ala Gln
                485                 490                 495
Lys Gly Arg Thr Gln Leu Cys Ala Leu Leu Leu Ala His Gly Ala Asp
            500                 505                 510
Pro Thr Leu Lys Asn Gln Glu Gly Gln Thr Pro Leu Asp Leu Val Ser
        515                 520                 525
Ala Asp Asp Val Ser Ala Leu Leu Thr Ala Ala Met Pro Pro Ser Ala
    530                 535                 540
Leu Pro Ser Cys Tyr Lys Pro Gln Val Leu Asn Gly Val Arg Ser Pro
545                 550                 555                 560
Gly Ala Thr Ala Asp Ala Leu Phe Gln Val His Leu Ala His Gln Ala
                565                 570                 575
Phe Leu Gln Pro Ala Val Leu Thr Thr Ile Trp Glu Phe Ser Glu Leu
            580                 585                 590
Ser Ser Val Val Ser Ser Ser Gly Thr Glu Gly Ala Ser Ser Leu Glu
        595                 600                 605
Lys Lys Glu Val Pro Gly Val Asp Phe Ser Ile Thr Gln Phe Val Arg
    610                 615                 620
Asn Leu Gly Leu Glu His Leu Met Asp Ile Phe Glu Arg Glu Gln Ile
625                 630                 635                 640
Thr Leu Asp Val Leu Val Glu Met Gly His Lys Glu Leu Lys Glu Ile
                645                 650                 655
Gly Ile Asn Ala Tyr Gly His Arg His Lys Leu Ile Lys Gly Val Glu
            660                 665                 670
Arg Leu Ile Ser Gly Gln Gln Gly Leu Asn Pro Tyr Leu Thr Leu Asn
        675                 680                 685
Thr Ser Gly Ser Gly Thr Ile Leu Ile Asp Leu Ser Pro Asp Asp Lys
    690                 695                 700
Glu Phe Gln Ser Val Glu Glu Glu Met Gln Ser Thr Val Arg Glu His
705                 710                 715                 720
Arg Asp Gly Gly His Ala Gly Gly Ile Phe Asn Arg Tyr Asn Ile Leu
                725                 730                 735
Lys Ile Gln Lys Val Cys Asn Lys Lys Leu Trp Glu Arg Tyr Thr His
            740                 745                 750
Arg Arg Lys Glu Val Ser Glu Glu Asn His Asn His Ala Asn Glu Arg
        755                 760                 765
Met Leu Phe His Gly Ser Pro Phe Val Asn Ala Ile Ile His Lys Gly
    770                 775                 780
Phe Asp Glu Arg His Ala Tyr Ile Gly Gly Met Phe Gly Ala Gly Ile
785                 790                 795                 800
Tyr Phe Ala Glu Asn Ser Ser Lys Ser Asn Gln Tyr Val Tyr Gly Ile
                805                 810                 815
Gly Gly Gly Thr Gly Cys Pro Val His Lys Asp Arg Ser Cys Tyr Ile
            820                 825                 830
Cys His Arg Gln Leu Leu Phe Cys Arg Val Thr Leu Gly Lys Ser Phe
        835                 840                 845
Leu Gln Phe Ser Ala Met Lys Met Ala His Ser Pro Pro Gly His His
    850                 855                 860
Ser Val Thr Gly Arg Pro Ser Val Asn Gly Leu Ala Leu Ala Glu Tyr
```

```
865                 870                 875                 880
Val Ile Tyr Arg Gly Glu Gln Ala Tyr Pro Glu Tyr Leu Ile Thr Tyr
                885                 890                 895
Gln Ile Met Arg Pro Glu Gly Met Val Asp Gly
            900                 905

      <210> 11
      <211> 10
      <212> PRT
      <213> Homo sapiens

      <400> 11
Asp Leu Ala Asp Pro Ser Ala Lys Ala Val
 1               5                  10

      <210> 12
      <211> 10
      <212> PRT
      <213> Homo sapiens

      <400> 12
Leu Leu Ser Tyr Gly Ala Asp Pro Thr Leu
 1               5                  10

      <210> 13
      <211> 10
      <212> PRT
      <213> Homo sapiens

      <400> 13
Leu Leu Ala His Gly Ala Asp Pro Thr Leu
 1               5                  10

      <210> 14
      <211> 10
      <212> PRT
      <213> Homo sapiens

      <400> 14
Gly Met Phe Gly Ala Gly Ile Tyr Phe Ala
 1               5                  10

      <210> 15
      <211> 9
      <212> PRT
      <213> Homo sapiens

      <400> 15
Ala Thr Ala Asp Ala Leu Phe Gln Val
 1               5

      <210> 16
      <211> 222
      <212> DNA
      <213> Homo sapiens

      <400> 16
aagtttgagg cctctggctt ctgctatgtc aacgacattg tgattggcat cctggagctg      60
ctcaagtacc accctcgggt gctctacatt gacattgaca tccaccatgg tgacggggtt     120
caagaagctt tctacctcac tgaccgggtc atgacggtgt ccttccacaa atacggaaat     180
tacttcttcc ctggcacagg tgacatgtat gaagtcgggg ca                         222
```

<210> 17
<211> 74
<212> PRT
<213> Homo sapiens

<400> 17

```
Lys Phe Glu Ala Ser Gly Phe Cys Tyr Val Asn Asp Ile Val Ile Gly
 1               5                  10                  15
Ile Leu Glu Leu Leu Lys Tyr His Pro Arg Val Leu Tyr Ile Asp Ile
            20                  25                  30
Asp Ile His His Gly Asp Gly Val Gln Glu Ala Phe Tyr Leu Thr Asp
        35                  40                  45
Arg Val Met Thr Val Ser Phe His Lys Tyr Gly Asn Tyr Phe Phe Pro
    50                  55                  60
Gly Thr Gly Asp Met Tyr Glu Val Gly Ala
65                  70
```